Artificial Intelligence and Deep Learning for Screening and Risk Assessment of Cancers

Authors:

Mehrdad Farrokhi
ERIS Research Institute

Soheila Jafari Khouzani
University of New Mexico

Masoud Farrokhi
ERIS Research Institute

Hediyeh Jalayeri
Iran University of Medical Sciences

Pooya Faranoush
Islamic Azad University; Science & Research Branch

Mahdi Babaei
Isfahan University of Medical Sciences

Shadi Nouri
Arak University of Medical Sciences

Mehrdad SalekShahabi
Tabriz Azad University of Medical Sciences

Mohammad Javad Taghipour
Shiraz University of Medical Sciences

Fatemeh Tavakoli
Shiraz University of Medical Sciences

Erfan Kohansal

Shiraz University of Medical Sciences

Mohammad Khosousi Sani
Shahid Beheshti University of Medical Sciences

Atousa Moghadam Fard
ERIS Research Institute

Sahba Emtehani
Xi'an Jiaotong University

Roya Khorram
Shiraz University of Medical Sciences

Mehdi Lotfinezhad
Guilan University of Medical Sciences

Habib Azimi
Tabriz University of Medical Sciences

Nazanin Zafarani
Semnan University of Medical Sciences

Saharnaz Esmaeili
Shahid Beheshti University of Medical Sciences

Yalda Zhoulideh
Islamic Azad University of Tabriz

Soheil Shahbazi
Shahid Beheshti University of Medical Sciences

Tara Mahmoodi
Tehran University of Medical Sciences

Zahra Pirouzan
Shahid Sadoughi University of Medical Sciences

Mahmonir Bayanati
West Tehran Branch, Islamic Azad University

Alireza Ghajary
Mashhad University of Medical Sciences

Navid Zandi Atashbar
Isfahan University of Technology

Mozhdeh Mohammadi Visroudi
Guilan University of Medical Sciences

Arnoosh Karimimoghadam
Islamic Azad University, Sari Medical Branch

Behnoosh Sabaghi
Isfahan University of Medical Sciences

Erfan Bozorgzade Ahmadi
Guilan University of Medical Sciences

Ehsan Fayyazishishavan
The University of Texas Health Science Center at Houston (UTHealth)

Amir Ghaleh Ghafi
Islamic Azad University Gorgan Branch

Hournaz Hassanzadeh
Iran University of Medical Sciences

Bahare Firouzbakht
Shiraz University of Medical Sciences

Negar Radpour
Shahid Beheshti University of Medical Sciences

Hamidreza Momeni
Shahid Beheshti University of Medical Sciences

Shahriar Zohourian Shahzadi
Iran University of Medical Sciences

Sahar Sanjarian
Islamic Azad University, Tehran Medical Branch

Shamim Chinian
Tehran University of Medical Sciences

Mona Mohajer Tehrani
Tehran University of Medical Sciences

Ali Ebrahimi
Medical University of Silesia

Zahrasadat Rezaei
Tehran University of Medical Sciences

Babak Goodarzy
Iran University of Medical Sciences

Amir Moeini
ERIS Research Institute

Fatemeh Taheri
ERIS Research Institute

Sahar Hassantash
University of Miami

Book Details:

Publisher: Kindle

Publication Date: January 2024

Language: English

Dimensions: 5 x 0.39 x 8 inches

ISBN-13: 979-8873942442

Contents

Chapters

1- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF ENDOCRINE AND GASTROINTESTINAL CANCERS

Background

Cancer remains a formidable adversary in the realm of human health and continues to be battled through global medical research and treatment. Endocrine and gastrointestinal cancers, among the many types that afflict humans, are the primary causes of morbidity and mortality. These tumors target vital organs and systems like the pancreas, thyroid, and digestive system, necessitating early diagnosis and precise evaluation for effective intervention.

Traditionally, cancer diagnosis and risk assessment relied on established methods, such as clinical examination, genetic screening, and clinical evaluation. While these methods can enhance outcomes, they also have their limitations. Endocrine and gastrointestinal diseases often exhibit poor behavior, eluding detection until they reach an advanced stage, thereby diminishing the prospects of successful treatment.

Artificial intelligence (AI) has emerged as a revolutionary force in healthcare, particularly in the early detection and diagnosis of cancer. Endocrine and gastrointestinal cancers, given their distinct outcomes and the urgent need for early identification, present significant challenges. However, artificial intelligence has stepped in to address these issues and plays a crucial role in transforming cancer diagnosis.

One of the primary applications of artificial intelligence in cancer diagnosis involves the analysis of medical images. Radiological imaging, such as CT scans, MRIs, and x-rays, plays a vital role in identifying endocrine and gastrointestinal cancers. Artificial intelligence algorithms can analyze these images with unparalleled precision and speed. They can often detect minute abnormalities and suspicious growths that may indicate cancer before they become visible to the naked eye. Early diagnosis is paramount for improving patient outcomes, as cancers in their early stages are generally more manageable.

AI can also aid in personal risk assessment and classification. By processing vast amounts of information, including intelligence, genetics, family history, lifestyle, and biomarkers, it can predict an individual's likelihood of developing endocrine or stomach cancer. These risk prediction models facilitate screening and preventative measures for high-risk groups. This personalized approach not only enhances the accuracy of cancer tests but also alleviates the burden on healthcare systems by

focusing on those who need it most.

Artificial intelligence can help mitigate the occurrence of false positive results, a common challenge in cancer diagnosis. AI systems can enhance the accuracy of measurements by adjusting algorithms and integrating multiple patient data points. This reduces the need for unnecessary examinations or procedures, minimizing patient stress and medical costs.

Artificial intelligence expedites the scanning process by swiftly processing extensive medical information, far faster than human experts. This speed is crucial in time-sensitive scenarios, such as emergencies or urgent cases. In the diagnosis of colon cancer, artificial intelligence can assist doctors in analyzing biopsy samples. AI-powered image analysis enables the detection of subtle cellular and histopathological changes that are challenging to discern with the naked eye. This leads to more precise diagnoses and tailored treatment plans.

AI-driven monitoring solutions, including wearable devices and remote controls, can continuously monitor individuals at risk of endocrine and colon cancer. These systems detect early warning signs and promptly alert doctors, ensuring timely intervention and minimizing the risk of delayed diagnosis.

Introduction to Endocrine and Gastrointestinal Cancers

Endocrine and gastrointestinal cancers are a significant burden on global healthcare systems, with high morbidity and mortality rates. This chapter explores the role of artificial intelligence (AI) in the screening and risk assessment of these cancers. By leveraging AI technologies, we can improve early detection, risk prediction, and personalized treatment strategies for patients with endocrine and gastrointestinal cancers.

AI-Based Imaging Techniques for Screening

AI-based imaging techniques have revolutionized cancer screening by providing accurate and efficient analysis of medical images. In this section, we discuss the application of AI algorithms, such as convolutional neural networks (CNNs), in the interpretation of imaging modalities like computed tomography (CT), magnetic resonance imaging (MRI), and endoscopy. We explore how AI can enhance the accuracy and speed of cancer detection, leading to improved patient outcomes.

Risk Assessment Models in Endocrine Cancers

Accurate risk assessment is crucial for effective management of endocrine cancers. AI algorithms can analyze diverse patient data, including genetic markers, clinical parameters, and biomarkers, to develop risk prediction models. This section focuses on the development and validation of AI-driven

risk assessment models for endocrine cancers. We discuss the integration of machine learning techniques, such as support vector machines (SVMs) and deep learning, to identify individuals at high risk and enable targeted interventions.

Risk Assessment Models in Gastrointestinal Cancers

Gastrointestinal cancers encompass a wide range of malignancies, each with distinctive risk factors and behaviors. In this section, we explore the role of AI in developing risk assessment models for gastrointestinal cancers. AI algorithms can analyze clinical and molecular data, including tumor markers, histopathological features, and lifestyle factors, to predict cancer risk. We discuss the potential of AI in stratifying patients based on their risk profiles and guiding personalized surveillance and prevention strategies.

Integration of Multi-Omics Data for Risk Assessment

The integration of multi-omics data, such as genomics, transcriptomics, proteomics, and metabolomics, holds great promise in improving risk assessment accuracy. AI algorithms can analyze complex molecular data sets to identify patterns, genetic alterations, and molecular signatures associated with endocrine and gastrointestinal cancers. This section explores how AI-driven integration of multi-omics data can enhance risk prediction and facilitate targeted interventions for better patient outcomes.

AI-Enhanced Pathology and Histopathology Analysis

Pathology and histopathology analysis play a crucial role in the diagnosis, prognosis, and treatment planning for endocrine and gastrointestinal cancers. AI algorithms, such as deep learning and computer vision, can assist pathologists in analyzing histopathological images and identifying cancerous features. This section focuses on the application of AI in pathology and histopathology analysis, including tumor detection, grading, and prediction of treatment response.

AI-Driven Biomarker Discovery

Biomarkers play a vital role in cancer diagnosis, prognosis, and treatment selection. AI algorithms can analyze large-scale omics data sets to identify potential biomarkers associated with endocrine and gastrointestinal cancers. In this section, we discuss how AI-driven biomarker discovery can lead to the identification of novel diagnostic and prognostic markers, as well as predictive markers for treatment response. We also explore the challenges and opportunities in translating AI-driven biomarkers into clinical practice.

AI-Based Liquid Biopsy for Early Detection

Liquid biopsy, a non-invasive method for detecting and monitoring cancer, has gained significant attention in recent years. AI algorithms can analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other liquid biopsy biomarkers to detect early signs of endocrine and gastrointestinal cancers. This section explores the potential of AI-based liquid biopsy techniques in enabling early detection, monitoring treatment response, and detecting minimal residual disease.

Challenges and Limitations

While AI holds immense potential in the screening and risk assessment of endocrine and gastrointestinal cancers, several challenges and limitations need to be addressed. This section discusses the ethical, legal, and regulatory considerations surrounding AI implementation in cancer care. We also explore challenges related to data quality, algorithm transparency, and clinician acceptance. Understanding these challenges is essential for the successful integration of AI technologies into clinical practice.

Clinical Implementation and Workflow Integration

The successful integration of AI technologies into clinical workflows is crucial for their widespread adoption. In this section, we discuss the considerations and challenges involved in implementing AI-based screening and risk assessment tools in healthcare settings. We explore strategies for seamless integration into existing clinical workflows, addressing issues related to data privacy, interoperability, and user acceptance.

Validation and Clinical Utility of AI Models

Validating the accuracy and clinical utility of AI models is paramount for their reliable implementation. This section focuses on the validation of AI models for endocrine and gastrointestinal cancer screening and risk assessment. We discuss the importance of rigorous validation studies using diverse patient cohorts, real-world data, and comparison with standard diagnostic approaches.

Future Directions and Conclusion

In this final section, we outline the future directions and potential advancements in the role of artificial intelligence (AI) in the screening and risk assessment of endocrine and gastrointestinal cancers. AI technologies are continuously evolving, and their integration into clinical practice is expected to bring about significant improvements in cancer detection, risk prediction, and personalized treatment strategies.

One potential future direction is the development of AI algorithms that can leverage multimodal data integration. By combining imaging data, molecular profiling, and clinical information, AI

models can provide a more comprehensive and accurate assessment of cancer risk. This integration could lead to the development of more precise risk prediction models, guiding clinicians in making informed decisions regarding screening, surveillance, and intervention strategies.

Another promising area is the use of AI in real-time decision support systems. AI algorithms can analyze patient data in real-time, provide risk assessments, and offer treatment recommendations based on the latest evidence and guidelines. This integration of AI into clinical workflows can enhance the efficiency and effectiveness of cancer care, enabling timely interventions and improving patient outcomes.

Furthermore, the development of explainable AI models is essential for the wider adoption of AI in cancer screening and risk assessment. Explainable AI algorithms provide clear and interpretable explanations for their predictions, enabling clinicians to understand the underlying factors contributing to the risk assessment. This transparency is crucial for building trust and acceptance among healthcare providers and patients.

In conclusion, the role of AI in the screening and risk assessment of endocrine and gastrointestinal cancers is rapidly evolving. AI-based imaging techniques, risk prediction models, integration of multi-omics data, pathology analysis, liquid biopsy, and biomarker discovery are all contributing to improved cancer detection, risk assessment, and personalized treatment strategies. However, several challenges and limitations need to be addressed, including ethical considerations, data quality, algorithm validation, and clinical implementation. With continued research, collaboration, and innovation, AI has the potential to revolutionize cancer care, leading to earlier detection, more accurate risk assessment, and improved patient outcomes.

2- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF PEDIATRIC CANCERS

Introduction to Pediatric Cancers

Pediatric cancers are a diverse group of malignancies that affect children and adolescents. Early detection and accurate risk assessment are crucial for improving outcomes in pediatric oncology. In this chapter, we explore the role of artificial intelligence (AI) in the screening and risk assessment of pediatric cancers. We discuss the potential benefits, challenges, and current research in using AI to enhance early detection and risk prediction in this vulnerable population.

AI-Based Imaging Techniques for Pediatric Cancer Screening

AI-based imaging techniques have shown promise in the early detection of pediatric cancers. This section focuses on the application of AI algorithms, such as convolutional neural networks (CNNs), in analyzing imaging modalities like computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. We discuss how AI can

improve the accuracy and efficiency of cancer detection in pediatric patients, leading to timely interventions and improved outcomes.

Risk Assessment Models for Pediatric Cancers

Accurate risk assessment is essential for tailoring treatment strategies and optimizing outcomes in pediatric oncology. AI algorithms can analyze diverse patient data, including clinical features, genetic markers, and molecular profiles, to develop risk prediction models. Thissection explores the development and validation of AI-driven risk assessment models for pediatric cancers. We discuss the integration of machine learning techniques, such as decision trees and random forests, to identify high-risk patients and guide personalized treatment planning.

Integration of Multi-Omics Data for Risk Assessment

The integration of multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, holds great potential in improving risk assessment accuracy in pediatric cancers. AI algorithms can analyze complex molecular data sets to identify genetic alterations, molecular signatures, and potential therapeutic targets. This section discusses how AI-driven integration of multi-omics data can enhance risk prediction and facilitate the development of personalized treatment approaches for pediatric patients.

AI-Enhanced Pathology Analysis in Pediatric Cancers

Pathology analysis plays a crucial role in the diagnosis and classification of pediatric cancers. AI algorithms, such as deep learning and image analysis, can assist pathologists in analyzing histopathological images and identifying cancerous features with high precision. This section explores the application of AI in pathology analysis for pediatric cancers, including tumor detection, grading, and prediction of treatment response.

AI-Driven Biomarker Discovery in Pediatric Cancers

Biomarkers are essential for early detection, prognosis, and treatment selection in pediatric cancers. AI algorithms can analyze large-scale omics data sets to identify potential biomarkers associated with pediatric malignancies. This section focuses on the application of AI in biomarker discovery for pediatric cancers, including the use of machine learning algorithms for feature selection, validation, and translation into clinical practice.

AI-Based Liquid Biopsy for Pediatric Cancer Screening

Liquid biopsy, a non-invasive method for detecting and monitoring cancer, holds promise in pediatric oncology. AI algorithms can analyze circulating

tumor DNA (ctDNA), circulating tumor cells (CTCs), and other liquid biopsy biomarkers to detect early signs of pediatric cancers. This section explores the potential of AI-based liquid biopsy techniques in enabling early detection, monitoring treatment response, and detecting minimal residual disease in pediatric patients.

Challenges and Limitations in AI Adoption for Pediatric Cancers

While AI offers significant potential in pediatric cancer screening and risk assessment, several challenges and limitations need to be addressed. This section discusses ethical considerations, data quality, algorithm validation, and regulatory hurdles associated with the adoption of AI in pediatric oncology. Understanding and addressing these challenges are crucial for the responsible and effective implementation of AI technologies in clinical practice.

Clinical Implementation and Workflow Integration

The successful integration of AI technologies into clinical workflows is essential for their widespread adoption in pediatric oncology. This section focuses on the considerations and challenges involved in implementing AI-based screening and risk assessment tools in pediatric cancer care. We discuss strategies for seamless integration into existing clinical workflows, addressing issues related to data privacy, interoperability, and user acceptance.

Validation and Clinical Utility of AI Models in Pediatric Cancers

Validating the accuracy and clinical utility of AI models is paramount for their reliable implementation in pediatric oncology. This section emphasizes the importance of rigorous validation studies using diverse patient cohorts, real-world data, and comparison with standard diagnostic approaches. We explore the potential challenges and opportunities in translating AI-driven models into clinical practice for the benefit of pediatric cancer patients.

Ethical Considerations in AI Implementation for Pediatric Cancers

The use of AI in pediatric cancer care raises important ethical considerations. This section explores the ethical implications of AI adoption in screening and risk assessment, including issues related to data privacy, consent, equity, and the role of healthcare providers in decision-making. We discuss the need for transparent and accountable AI systems that prioritize the well-being and best interests of pediatric patients.

AI-Assisted Treatment Planning and Monitoring in Pediatric Cancers

Effective treatment planning and monitoring are essential components of pediatric cancer care. Artificial intelligence (AI) can play a significant role in assisting healthcare providers in these processes, improving treatment outcomes and reducing the risk of adverse events. This section explores the applications of AI in treatment planning and monitoring in pediatric cancers.

AI for Treatment Planning

AI algorithms can analyze complex patient data, including clinical information, imaging results, and molecular profiles, to assist in treatment planning for pediatric cancers. By integrating and analyzing these diverse data sets, AI can provide valuable insights and recommendations for personalized treatment strategies. For example, AI can help identify optimal chemotherapy regimens, radiation therapy plans, and surgical interventions based on individual patient characteristics, tumor biology, and treatment response prediction.

AI can also aid in the identification of potential treatment-related toxicities and their management. By analyzing patient data and considering factors such as age, genetic variations, and previous treatment history, AI algorithms can assist in predicting and mitigating treatment-related side effects. This information can help healthcare providers tailor treatment plans to reduce toxicity and improve patient quality of life.

AI for Treatment Monitoring

Monitoring treatment response is crucial in pediatric oncology to assess the effectiveness of therapy and make timely adjustments when needed. AI can assist in this process by analyzing imaging data, laboratory results, and clinical information over time. By comparing current data with baseline measurements and established response criteria, AI algorithms can provide objective evaluations of treatment response and detect early signs of disease progression or relapse.

AI can also facilitate the identification of novel biomarkers or imaging features that correlate with treatment response. By analyzing large datasets, AI algorithms can uncover patterns and associations that may not be readily apparent to human observers. These insights can aid in the development of more accurate and predictive response assessment tools, enabling healthcare providers to make informed decisions regarding treatment adjustments or alternative therapies.

Furthermore, AI can assist in the interpretation of longitudinal patient data and identify trends or patterns that may be indicative of treatment efficacy or toxicity. By continuously monitoring and analyzing data, AI algorithms can provide real-time feedback to healthcare providers, facilitating proactive interventions and optimizing treatment outcomes.

3- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF SKIN CANCERS

Introduction to Skin Cancer

Skin cancer is a prevalent and potentially deadly disease that arises from the uncontrolled growth of abnormal cells in the skin. It is primarily caused by cumulative exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is a significant public health concern worldwide, and its incidence has been steadily increasing over the past few decades.

There are three main types of skin cancer: basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. BCC and SCC are collectively referred to as non-melanoma skin cancers and are the most common types. Although they tend to have a lower mortality rate compared to melanoma, they can still cause significant morbidity if left untreated. Melanoma, although less common, is the most aggressive form of skin cancer and has a higher potential to spread to other parts of the body.

Risk factors for developing skin cancer include fair skin, a history of sunburns, excessive sun exposure, a family history of skin cancer, a weakened immune

system, and certain genetic conditions. Individuals with a higher risk of skin cancer should undergo regular screening and risk assessment to detect any abnormalities at an early stage when treatment is most effective.

Skin cancer screening involves a thorough examination of the skin, typically performed by a healthcare professional or dermatologist. It aims to identify suspicious lesions or moles that may require further evaluation. Risk assessment, on the other hand, involves evaluating individual risk factors to determine the likelihood of developing skin cancer. This process helps tailor preventive measures and surveillance strategies for individuals at higher risk.

Early detection of skin cancer is crucial for successful treatment and improved outcomes. When diagnosed at an early stage, skin cancer is typically highly treatable, with high cure rates. However, if left undiagnosed and untreated, it can lead to more advanced stages, requiring more aggressive treatment and potentially spreading to other organs.

The introduction of artificial intelligence (AI) in skin cancer screening and risk assessment holds great promise. AI algorithms can analyze vast amounts of data, including images, patient history, and risk factors, to provide accurate and efficient diagnostic and prognostic information. By leveraging AI's capabilities, healthcare professionals can enhance their ability to detect skin cancer early and make more informed decisions regarding treatment and surveillance.

In conclusion, skin cancer is a significant and increasingly prevalent disease with potentially severe consequences if not detected and treated early. Screening and risk assessment play vital roles in identifying individuals at risk or those with suspicious lesions for further evaluation. The integration of AI in skin cancer screening and risk assessment has the potential to revolutionize the field by improving accuracy, efficiency, and patient outcomes. Through the development and implementation of AI-driven tools and algorithms, healthcare professionals can optimize their ability to detect and manage skin cancer, ultimately saving lives and reducing the burden of this disease.

Skin cancer is a prevalent global disease, and its incidence rates continue to rise. Early detection plays a crucial role in improving prognosis and survival rates. However, accurate diagnosis often requires extensive clinical expertise and specialized equipment. Unfortunately, there is a shortage of dermatologists worldwide, leading to challenges in accessing timely diagnoses.

Artificial intelligence (AI) and machine learning (ML), particularly deep learning (DL), offer promising solutions to enhance skin cancer screening, risk assessment, and diagnostic expertise accessibility. DL involves the use of multi-layered neural networks that can automatically learn complex features and patterns in data. This makes

DL particularly well-suited for analyzing visual medical data, such as dermoscopy images of skin lesions. Several studies have developed DL systems capable of classifying lesions and diagnosing melanoma with accuracy comparable to expert dermatologists. Some of these systems employ convolutional neural networks (CNNs), which excel at image analysis, enabling them to distinguish between benign moles and malignant lesions through training on labeled image datasets.

However, many existing systems are proof-of-concepts evaluated on standardized images rather than real-world clinical data. It is crucial to validate these systems using diverse and real-world data before their clinical use. Concerns also exist regarding safety, interpretability, and biases in training data. Collaborative partnerships among technology developers, clinicians, and ethicists can help address these issues effectively.

Overview of Screening and Risk Assessment

Skin cancer screening and risk assessment are essential components of early detection and prevention strategies. This section provides an overview of the methods and tools commonly used in skin cancer screening and the factors considered in risk assessment. Skin cancer screening involves a comprehensive examination of the skin to identify any suspicious lesions or moles that may be indicative of skin cancer.

Dermatologists and healthcare professionals use various techniques during the screening process, such as visual inspection, dermoscopy, and total body photography.

Visual inspection is the primary method used in skin cancer screening. It involves a systematic examination of the skin, looking for any changes in color, size, shape, or texture of moles or lesions. Dermoscopy, also known as dermatoscopy or epiluminescence microscopy, is a non-invasive technique that uses a handheld device with magnification and light to visualize structures within the skin. It provides additional information about the patterns and structures of moles and lesions, aiding in the detection of early signs of skin cancer.

Total body photography is a method that involves capturing high-resolution images of the entire body surface, including both macroscopic and dermoscopic images. These images serve as a baseline for future comparisons, helping to identify any new or changing lesions. Risk assessment aims to identify individuals who are at a higher risk of developing skin cancer. Several factors are considered during the risk assessment process. These include personal and family history of skin cancer, skin type, sun exposure history, presence of atypical moles, and other risk factors such as immunosuppression or genetic conditions.

Personal and family history of skin cancer can provide valuable insights into an individual's

predisposition to the disease. Individuals with a previous history of skin cancer or a family history of the disease are considered at higher risk and may require more frequent screening and surveillance.

Skin type is another important factor in risk assessment. Fair-skinned individuals who burn easily and have a lower tolerance to sun exposure are at a higher risk of developing skin cancer. Skin types with more pigment, such as darker skin tones, are generally at a lower risk but are not immune to developing skin cancer. Sun exposure history, including occupational exposure, recreational activities, and sunburns, is a significant risk factor. Prolonged exposure to UV radiation, whether from the sun or artificial sources, increases the risk of developing skin cancer. Presence of atypical moles, also known as dysplastic nevi, can indicate an increased risk of developing melanoma. These moles may exhibit irregular borders, color variations, or larger sizes compared to normal moles. In addition to these factors, certain genetic conditions and immunosuppression can also contribute to an increased risk of developing skin cancer.

Combining screening and risk assessment allows healthcare professionals to tailor their approach to each individual's needs. High-risk individuals may undergo more frequent screenings or additional diagnostic tests, while low-risk individuals may require less intensive surveillance.

In conclusion, skin cancer screening and risk assessment are crucial components of early detection and prevention strategies. Visual inspection, dermoscopy, and total body photography are common methods used in screening. Risk assessment considers factors such as personal and family history, skin type, sun exposure history, presence of atypical moles, and other risk factors. By implementing comprehensive screening and risk assessment protocols, healthcare professionals can identify individuals at higher risk and detect skin cancer at its early stages, leading to better outcomes and improved patient care.

Applications in Primary Care

DL tools hold promise in primary care settings, where most patients initially present with skin concerns. Technologies like smartphone apps have the potential to improve diagnostic triage, reducing unnecessary referrals and biopsies. However, limited evidence is available for primary care settings, as most research focuses on specialist populations with a higher disease prevalence. Further research on accuracy in primary care settings is necessary before routine adoption.

Multimodal Approaches

Combining DL with other data modalities can enhance assessment outcomes. For instance, infrared thermography can detect thermal differences between lesions, and DL algorithms can analyze thermograms alongside visual images.

Some systems also incorporate patient factors such as age and genetics. These multimodal approaches have the potential to enhance risk assessment and diagnostic accuracy.

Challenges

Several challenges remain in developing clinically useful DL tools for skin cancer screening. Many consumer apps available are unvalidated, posing safety risks. Regulations in this field lag behind rapid technological advancements, emphasizing the need for close collaboration among technology companies, clinicians, regulators, and patients to ensure safety. Workflow and implementation challenges exist in diverse real-world clinical settings, and user-friendly integration with existing systems is crucial for practitioner acceptance and patient benefit. Further studies investigating the impact on clinical efficiency, costs, and access are essential. Additionally, increasing model interpretability is vital to address concerns related to the "black box" nature of DL algorithms. Ethical considerations surrounding training data biases and privacy also demand ongoing scrutiny.

In conclusion, DL holds tremendous promise in augmenting clinician expertise and improving patient outcomes in skin cancer screening and risk assessment. However, careful development and evidence-based implementation are crucial to realize its benefits safely and equitably. Continued partnerships between technology and clinical experts, along with active patient involvement, will facilitate the development of ethical and effective AI tools that patients and healthcare providers can trust.

4- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF BREAST AND LUNG CANCERS

Role of AI in Lung Cancer Screening

Lung cancer, the leading cause of malignancy-related death worldwide, is often diagnosed at a late stage, contributing to its high mortality rate. Approximately 7% of cases do not exhibit specific symptoms, making accurate screening tests crucial. Various screening methods have been proposed, including sputum and blood cell analysis, breath tests, and the utilization of imaging modalities. Among these, the latter methods have shown better results.

Lung cancer can manifest as a pulmonary nodule, a mass (measuring larger than 3cm), ground glass opacity, or consolidation. Low-dose computed tomography (LDCT) has proven to be superior to chest X-ray (CXR) in the early diagnosis of lung malignancy and has been shown to improve patient survival.

AI-assisted screening models based on CXR have been developed, with promising results. One of the most reliable models is CheXNet, a deep learning

algorithm trained to diagnose 14 lung disorders, including pulmonary neoplasms. CheXNet has exhibited a high level of diagnostic performance. AI programs have also been developed based on LDCT for nodule detection and estimation of nodule density. Examples of such programs include Lung Nodule Analysis 2016 (LUNA16) and Automated Nodule Detection 2009 (ANODE09). These programs serve as second readers and can help radiologists save time.

Another method of lung cancer screening involves the detection of tumor markers such as long non-coding RNAs (lncRNAs). AI-based algorithms, including the Lasso algorithm, have been developed with acceptable results.

In the pathogenesis of lung cancer, mutated genes play a known role. It has been hypothesized that specific gene mutations are associated with changes in the arrangement and appearance of tumor cells in pathology samples. Coudray developed a neural network model with an accuracy ranging from 73.3% to 85.6%, capable of predicting the presence of six mutated genes by analyzing pathological images.

Lung cancer, scientifically known as Primary bronchogenic carcinoma, is the most common type of cancer that affects the lungs worldwide. Among different forms of cancer, it receives significant attention due to its high morbidity and fatality rate (18.0%), which is almost double that of colorectal cancer (9.4%). Like other cancers, early diagnosis plays a key role in prompt treatment and improved prognosis. In the early stages of cancer, pulmonary nodules can be detected in 22.0-59.7% of cases, although the overall rate of malignant nodules is less than 5%. Additionally, differentiating between lung cancer and tuberculosis (TB) poses a significant challenge, even for trained radiologists, leading to false-positive lung cancer diagnoses. This can cause unnecessary anxiety and economic burdens for patients and society, as well as incorrect treatment for the underlying disease. To address these challenges and improve diagnosis, prognostic prediction, and treatment, AI algorithms have been extensively studied and applied in recent years. AI is a comprehensive concept based on computational studies using datasets, which can include various techniques to create models based on available data such as known cancer characteristics, images, CT, etc., in order to predict new cases of the disease. ML, NN, DL, CV, and NLP are some of the AI techniques used. To achieve this goal, the dataset is typically divided into two main subsets: a training set for model development and a validation/prediction set to evaluate the model's performance. To provide further insights, this section highlights some recently reported cases.

In a study by S. Buosi and colleagues, ML was utilized to predict early-stage lung cancer cells using aneuploidy imputation scores, achieving a precision of 82% and a specificity of 91% in predicting outcomes for over 200 patients. Another report

by W.Y. Cheung and colleagues explored treatment patterns in patients with advanced lung cancer using AI techniques and real-world data (RWD) extraction, resulting in an overall accuracy of 82%. Furthermore, AI enables therapists to reduce radiation doses in CT scans without misinterpreting actionable pulmonary nodules during lung cancer screening.

Role of AI in Breast Cancer Screening

Breast cancer is the most common malignancy among women and ranks as the second leading cause of cancer-related mortality. Several imaging modalities, such as sonography, mammography, and magnetic resonance imaging (MRI), are available for screening and early detection of small non-palpable breast neoplasms. Mammography is the preferred choice due to its sensitivity in detecting small lesions or malignant calcifications, as well as its cost-effectiveness. Sonography is operator dependent, while MRI is primarily used for high-risk patients.

AI models, such as computer-aided diagnosis (CAD) with image analyzing approaches, have been introduced for breast cancer screening. These models have assisted radiologists in detecting tiny abnormalities. However, they have also led to a higher rate of false-positive biopsy results. Therefore, AI-assisted image interpretation should be considered as complementary or secondary review, as its performance is shown to be inferior to that of a human radiologist.

Newer mammographic AI models, such as VGG16, have exhibited higher accuracy compared to older types like AlexNet, GoogleNet, and EfficientNet models. In addition to tumor detection, mammographic AI models have been proposed and utilized for identifying scattered or heterogeneous densities using convolutional neural networks (CNN), as well as subtype classification using VGGNet-based CNN.

MRI is the most sensitive imaging tool for diagnosing breast cancer, but it is reserved for high-risk patients, complicated cases, or cases prior to neoadjuvant chemotherapy due to its higher cost. Winkler introduced an MRI-deep learning application that identifies MRI images containing tumors, thus enhancing the speed of interpretation by radiologists.

In conclusion, AI-assisted imaging-based techniques aid radiologists in detecting smaller lesions, saving time, and alleviating high workloads. However, more accurate programs are needed for independent image interpretation.

Breast cancer is the most prevalent form of cancer diagnosed in females worldwide, responsible for a significant number of cancer-related fatalities, approximately 15%, over the past decades. It is estimated that by 2025, there will be over 2.4 million diagnosed cases. Early diagnosis is crucial for effective treatment, and mammography

is widely used for breast screening, aiming to detect suspicious abnormalities through digital mammograms and reduce mortality rates. However, relying solely on mammography, using X-ray, ultrasound, or MRI, poses challenges such as false-positive detections or missed cancers, leading to unnecessary investigations and the development of aggressive tumors. Additionally, the shortage of breast radiologists combined with increasing demands results in a time-consuming process. As a result, automated algorithms based on artificial intelligence (AI) have been implemented to facilitate early diagnosis and treatment of breast cancer.

AI, as a computational tool, has made significant contributions in overcoming clinical challenges in oncology, including the detection, treatment, and prognosis of tumors. Machine learning (ML) techniques utilize data sets obtained from improved digital mammograms, which may involve background removal, and incorporate risk factors such as age range, family history, mammographic density, and BRCA gene tests to diagnose early tumors and control tumor growth or metastasis. Typically, the initial data set is divided into at least two subsets: a training set used to create the classification model employing specific ML methods, and an external prediction or validation set used to assess the model's performance. The potential of AI in successfully detecting breast tissue tumors has garnered significant attention, leading to numerous studies in this field.

For instance, A.M. Hasan and colleagues developed a classification method for molecular subtypes of breast cancer using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in combination with convolutional neural networks (CNN) and support vector machines (SVM). They achieved an accuracy of 99.78% and an area under the curve (AUC) of 100% with low complexity. In another study, Q. Huang and colleagues introduced a diagnostic classification method for breast cancer using an improved Chef-Based Optimization algorithm to eliminate image noise and the optimal SqueezeNet model on the database of the Mammographic Image Analysis Society (MIAS). Additionally, Y.H. El-Sharkawy and colleagues discriminated between benign and malignant breast tissues by analyzing the reflection and transmission of diffused light in the 400-900 nm range, considering the differences in chemical structures, refractive indexes, and dielectric values caused by changes in cancer cells. They employed the K-means clustering algorithm. Furthermore, O. Haji and colleagues estimated breast density, a significant risk factor for breast cancer, using AI to analyze mammographic images with two CNN architectures that combined superpixel generation and radiomic ML, achieving an AUC of 0.612.

In conclusion, AI-based techniques, particularly those utilizing ML methods, have made impressive contributions to the detection, treatment, and prognosis of breast cancer. These techniques

leverage improved digital mammograms and incorporate various risk factors to diagnose tumors at an early stage and monitor tumor growth or metastasis. Ongoing research continues to explore the potential of AI in breast cancer detection and treatment.

5- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF ORAL CANCERS

Introduction to Oral Cancers

Oral cancer is a significant global health issue, encompassing malignancies that affect various parts of the mouth, including the lips, tongue, cheeks, gums, and the floor and roof of the mouth. It is estimated that oral cancer accounts for approximately 3% of all cancers worldwide. The incidence of oral cancer varies across different regions, with higher rates reported in South and Southeast Asia, parts of Europe, and certain regions of Africa.

The development of oral cancer is often associated with multiple risk factors. The most common risk factors include tobacco and alcohol use. Smoking cigarettes, cigars, or pipes, as well as using smokeless tobacco products, significantly increases the risk of developing oral cancer. Excessive alcohol consumption, particularly in combination with tobacco use, further amplifies the risk.

Another significant risk factor for oral cancer is infection with certain strains of the human papillomavirus (HPV), particularly HPV-16 and HPV-18. HPV-related oral cancers tend to occur in the oropharynx and are more common in younger individuals. Other risk factors include poor oral hygiene, chronic irritation from ill-fitting dentures or dental appliances, a diet lacking in fruits and vegetables, exposure to ultraviolet (UV) radiation, and a family history of oral cancer.

Early detection of oral cancer is critical for improving prognosis and treatment outcomes. However, oral cancers often go unnoticed until they have progressed to more advanced stages, making them more challenging to treat successfully. This is partly due to the anatomical location of the oral cavity, which may make visual inspection and manual palpation less effective in detecting early-stage lesions.

Traditional methods of oral cancer screening involve visual inspection of the oral cavity and palpation of the oral tissues to identify any abnormalities, such as red or white patches, ulcers, or lumps. These methods heavily rely on the expertise and experience of healthcare professionals, and their accuracy can vary depending on the observer's skills. As a result, there is a need for more objective and standardized approaches to oral cancer screening.

Additionally, risk assessment plays a critical role in identifying individuals who may be at a higher risk of developing oral cancer. Risk factors such as tobacco and alcohol use, HPV infection,

genetic predisposition, and certain oral lesions are taken into consideration. Evaluating these factors allows healthcare professionals to tailor preventive strategies, such as smoking cessation programs, to high-risk individuals.

In conclusion, oral cancer is a significant health concern with various risk factors contributing to its development. Early detection through effective screening methods and comprehensive risk assessment is crucial for improving patient outcomes. The limitations of traditional screening methods and the need for more objective approaches highlight the potential role of artificial intelligence in revolutionizing oral cancer screening and risk assessment. By leveraging AI algorithms and advanced imaging techniques, healthcare professionals can enhance their ability to detect oral cancer at early stages, leading to timely interventions, improved treatment outcomes, and ultimately, saving lives.

Oral cancer (OC) is ranked as the sixth most common cancer worldwide and is typically found in areas such as the inner lip, dorsum of the tongue, gingiva, hard/soft palate, buccal mucosa, and floor of the mouth. Asia has the highest reported incidence of OC, with a mortality rate of 73%. Delayed diagnosis leads to increased morbidity and mortality, highlighting the need for modern techniques like artificial intelligence (AI) to screen high-risk populations and save lives.

A crucial strategy for preventing OC is the identification of premalignant lesions, which are morphologically altered tissues with an elevated risk of cancer progression. These lesions can be detected through clinical examination. Y et al. utilized machine learning trained on intraoral photographs to distinguish between OC, premalignant lesions, and clinically normal sites. The results showed that machine learning either matched or exceeded the diagnostic accuracy of human specialists in detecting oral squamous cell carcinoma (OSCC) and premalignant conditions. Therefore, machine learning can be a cost-effective and non-invasive tool for preventing OC.

In another study, Talwar et al. used smartphone-captured images to create an AI diagnostic model for premalignant lesions and OCs. The most effective algorithms were DenseNet and Swin (Base), which achieved sensitivities of 85% and 86%, respectively. False positive results mainly included tobacco stains, physiologic melanosis, aphthous ulcer, and periodontal diseases, while false negatives included early with-red sites, gingival desquamation, and traumatic keratosis. Thus, AI-assisted screening of premalignant lesions and OCs using smartphone photographs would be particularly beneficial in underprivileged areas with limited healthcare access.

AI's potential in OC screening goes beyond intraoral photographs. For example, Xie et al. proposed AI-based surface-enhanced Raman spectroscopy (SERS) to detect gaseous methanethiol, a tumor biomarker,

in patients' exhaled breath. Their artificial neural network (ANN) model achieved a classification accuracy of 99% for the samples. Additionally, a systematic review evaluated the performance of AI in OC diagnosis using histopathological images, showing minimum accuracy rates of 90% and even reaching 100% in some investigations. AI-supported histopathological evaluations can help pathologists deliver more consistent diagnoses and reduce potential inaccuracies.

In another study, Banavar et al. demonstrated an 83% sensitivity and 98% specificity in a machine learning algorithm that analyzed metatranscriptomic data from saliva samples of individuals with premalignant lesions, OCs, and healthy controls. AI has also been utilized to identify individuals at high risk for OC based on behavioral and demographic factors. Rosma et al. used data from cancer patients, including age, gender, smoking habits, and alcohol intake, to develop fuzzy regression and fuzzy neural network models for evaluating OC risk. Their results showed that AI can match expert evaluations in predicting the risk of OC. Furthermore, Alhazmi et al. expanded the dataset by considering systemic medical conditions and clinic-pathological characteristics of patients in addition to existing risk factors.

OC presents a significant global health challenge with high rates of morbidity and mortality, emphasizing the importance of early identification and diagnosis. In recent years, artificial intelligence

(AI) has emerged as a valuable asset in screening and assessing the risk of OCs. AI systems have the ability to analyze large volumes of data, providing pathologists with faster and more accurate diagnostic insights. This improves the identification and understanding of OCs and their precursors. When combined with imaging techniques, AI significantly enhances OC prognosis by refining detection and diagnostic methods. The integration of AI tools in OC management offers numerous benefits, including improved accuracy, timely detection, streamlined operations, affordability, strategic treatment planning, and reduced diagnostic delays. By leveraging AI, precision, operational efficiency, and cost savings can be achieved in the management of OC.

Karadaghy et al. conducted a study using a machine-learning model to predict the 5-year survival rates of patients with oral squamous cell carcinoma. They analyzed data from 33,065 patients in the National Cancer Data Base collected between 2004 and 2011. The performance of their model was compared to the traditional TNM clinical staging system. The machine-learning model, incorporating various patient data, outperformed the TNM system. It achieved an area under the curve (AUC) of 0.80 and 71% accuracy, while the TNM system had an AUC of 0.68 and 65% accuracy. This research highlights the potential advantages of machine learning in refining patient risk assessments in today's data-rich medical environment.

Al-Rawi et al. explored the effectiveness of AI in diagnosing early-stage OC by reviewing 17 studies comprising 7245 patients and 69,425 images from four major databases. The research indicated that deep learning models achieved accuracy rates of 81-99.7% in OC detection, while supervised machine learning showed a wider range of 43.5-100% accuracy. Despite variations in the effectiveness of AI methods, the study emphasized the superior performance of deep learning, particularly deep convolutional neural networks, in early OC detection compared to traditional supervised machine learning techniques.

Speight et al. conducted a study to evaluate the effectiveness of a neural network in predicting the likelihood of individuals having malignant or pre-malignant oral lesions based on their risk habits, such as smoking and drinking. They analyzed data from 2027 adults and compared the predictions of the neural network to those of dental screeners. The dental screeners demonstrated a sensitivity of 0.74 and specificity of 0.99, while the neural network showed improved sensitivity at 0.80 but lower specificity at 0.77. The research suggests that while the neural network may identify high-risk individuals more sensitively, dental screeners remain more specific. However, the neural network offers a potentially cost-effective tool for early identification, potentially leading to timely OC screenings or preventive health education for those at risk.

In conclusion, the prevalence of OC worldwide calls for the adoption of advanced diagnostic tools. Artificial intelligence, particularly deep learning, has demonstrated its effectiveness in enhancing the detection process. While AI shows heightened sensitivity, traditional diagnostic approaches still excel in specificity. The integration of AI's computational capabilities with existing methodologies offers a promising avenue for swift and accurate diagnoses, representing a crucial step in addressing the persistent challenge of OC.

Current Challenges in Screening and Risk Assessment of Oral Cancers

While early detection and risk assessment are crucial in the management of oral cancers, the current methods of screening and risk assessment face several challenges. This section explores the limitations and complexities associated with traditional approaches, highlighting the need for more advanced techniques and tools.

One of the primary challenges in oral cancer screening is the reliance on visual inspection and manual palpation. The human eye and touch can miss subtle changes or early signs of oral cancer, especially in areas that are difficult to access or visualize. Additionally, the subjective nature of visual inspection and palpation can lead to variability in interpretation among healthcare professionals, affecting the accuracy and

consistency of the screening process.

Moreover, the complexity of risk assessment in oral cancers poses challenges. Oral cancer development is influenced by a combination of genetic, environmental, and lifestyle factors. Factors such as tobacco and alcohol use, HPV infection, genetic predisposition, and oral lesions need to be considered to assess an individual's risk accurately. However, integrating and evaluating these multifactorial aspects can be complex and time-consuming, requiring comprehensive data collection and analysis.

Another challenge relates to the identification and characterization of potentially malignant oral lesions. Not all oral lesions are cancerous, and distinguishing between benign and potentially malignant lesions can be challenging based solely on visual inspection. The differentiation often requires invasive procedures, such as biopsies, which may entail discomfort and risks for the patient.

Furthermore, access to oral cancer screening and risk assessment may be limited in certain regions, particularly in low-resource settings or areas with limited healthcare infrastructure. This can lead to delayed diagnosis and missed opportunities for early intervention.

To address these challenges, there is a growing need for more advanced and objective tools in oral cancer screening and risk assessment. This is where artificial intelligence (AI) can play a transformative role. AI algorithms can analyze vast amounts of data, detect patterns, and make accurate predictions, providing a more objective and standardized approach to oral cancer screening.

AI-powered imaging analysis can assist in the detection and characterization of oral lesions. Computer vision algorithms can analyze images captured through various imaging modalities, such as white light imaging, fluorescence imaging, or optical coherence tomography, to identify suspicious features associated with oral cancer. By leveraging AI, healthcare professionals can enhance their ability to detect early-stage lesions and differentiate between benign and potentially malignant lesions, leading to more accurate diagnoses.

Additionally, AI-driven risk assessment models can integrate multiple data points, including clinical information, patient demographics, lifestyle factors, genetic data, and biomarkers, to generate personalized risk profiles. These models can aid in identifying individuals at higher risk of developing oral cancer, enabling targeted prevention strategies, early detection, and appropriate surveillance protocols.

In conclusion, the current methods of oral cancer screening and risk assessment face challenges related to subjectivity, complexity, and limited access. The integration of AI in oral cancer screening can address these challenges by providing objective and accurate analysis of oral lesions and facilitating

comprehensive risk assessment. AI algorithms have the potential to augment healthcare professionals' expertise, leading to improved early detection, personalized risk assessment, and ultimately, better management of oral cancers.

6- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF HEAD AND NECK CANCERS

Introduction to Head and Neck Cancers

Head and neck cancers are a diverse group of malignancies that affect various anatomical sites, including the oral cavity, throat (pharynx), voice box (larynx), nasal cavity, sinuses, and salivary glands. They account for a significant portion of cancer cases globally, with varying incidence rates across different regions. These cancers can have a profound impact on patients' quality of life, affecting vital functions such as breathing, swallowing, and speaking.

Several risk factors contribute to the development of head and neck cancers. The most common risk factors include tobacco and alcohol use. Smoking cigarettes, cigars, pipes, or using smokeless tobacco significantly increases the risk of developing head and neck cancers. Excessive alcohol consumption, particularly when combined with tobacco use, further amplifies the risk.

In recent years, there has been an increase in the incidence of head and neck cancers linked to human papillomavirus (HPV) infection. HPV-related head and neck cancers, particularly those affecting the oropharynx, tend to occur in younger individuals and have distinct clinical and molecular characteristics compared to non-HPV-related cases.

Occupational exposures, such as exposure to certain chemicals and substances in certain industries like asbestos, nickel, wood dust, formaldehyde, and textile fibers, are also associated with an increased risk of head and neck cancers. Additionally, poor oral hygiene, chronic irritation from ill-fitting dentures or dental appliances, a diet low in fruits and vegetables, and a family history of head and neck cancers can contribute to the development of these malignancies.

Early detection plays a crucial role in improving outcomes for patients with head and neck cancers. Timely diagnosis allows for prompt initiation of appropriate treatment, which may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Additionally, early detection can help minimize the physical, emotional, and functional impact of these cancers on patients' lives.

Screening and risk assessment are essential components of effective head and neck cancer management. Screening involves the identification of individuals at risk or with early signs of the disease, while risk assessment aims to evaluate an individual's likelihood of developing head and neck cancer based on various factors.

Current screening methods for head and neck cancers typically involve a combination of physical

examination and patient-reported symptoms. Healthcare professionals conduct a thorough examination, looking for any abnormalities, such as lumps, ulcers, or changes in the mucosal lining of the mouth and throat. Patients are also asked about symptoms such as persistent hoarseness, difficulty swallowing, or a persistent sore throat. However, these methods heavily rely on the skills and experience of the healthcare provider and may not always detect early-stage cancers or subtle lesions.

Risk assessment in head and neck cancers involves evaluating multiple factors such as tobacco and alcohol use, HPV infection, occupational exposures, genetic predisposition, and family history. Assessing these factors can help identify individuals who may be at a higher risk of developing head and neck cancers and guide the implementation of preventive strategies and surveillance protocols.

In conclusion, head and neck cancers encompass a diverse group of malignancies with various risk factors. Early detection through effective screening methods and comprehensive risk assessment is crucial for improving patient outcomes. However, the current methods of screening and risk assessment face challenges related to subjectivity and the complexity of evaluating multiple risk factors. The integration of advanced technologies, such as artificial intelligence, has the potential to enhance head and neck cancer screening and risk assessment, leading to earlier detection, personalized care, and improved patient management.

Head and neck cancer is the seventh most common malignancy worldwide. It comprises a diverse group of cancers, with squamous cell carcinomas (SCC) being the most prevalent. These cancers typically arise from the epithelial lining of the oral cavity, sinonasal tract, pharynx, larynx, and salivary glands. Early detection of certain head and neck cancers can be challenging due to vague histories and non-specific diagnostic features.

Histopathological evaluation of tissue sections, along with clinical and radiological examinations, forms the foundation for the conventional diagnosis of head and neck cancer. However, recent advancements in cancer diagnostics have focused on digital image analysis and processing. This process involves extracting valuable information from images to identify clinically significant features through segmentation and label descriptions through classification.

Imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans are commonly used during the diagnosis, treatment, and follow-up of head and neck squamous cell carcinomas. To enhance the detection, screening, and prognosis of head and neck cancer, the use of artificial intelligence (AI) techniques and tools has been suggested to aid clinicians. Machine learning (ML) models are increasingly being developed to assist with disease segmentation

across various investigations during diagnosis, treatment planning, and treatment monitoring. AI-based tools can provide information that is not readily available to most pathologists today through light microscopy, such as prognosis reporting and predicting therapy response.

A review of diagnostic machine learning models for head and neck cancer by Bassani et al. revealed largely excellent accuracy rates above 90%. Deep learning methods are used to develop AI algorithms based on the concept of an artificial neural network trained using a large number of digital images, which are then used to classify unknown images. As the volume of training data increases, the general performance of the AI model improves.

Artificial intelligence (AI)-based prediction models have gained popularity due to the increasing number of independent prognostic and predictive markers. The hypothesis is that machine learning-based models can predict outcomes with greater accuracy than current models by combining clinical, biological, genomic, and radiologic data.

Whole slide imaging (WSI) has shown great diagnostic concordance compared to traditional light microscopy in anatomical pathology, despite technical and diagnostic issues. WSI offers advanced diagnosis and research capabilities. Convolutional neural networks (CNNs), which consist of multiple layers and use numerous hyperparameters to perform operations, are utilized for building classification models. CNNs enable the acquisition of various high-level characteristics from a set of image patches at different layers and testing them in classifiers.

Studies That Used AI in Detecting Head and Neck Cancers

Halicek et al. utilized a CNN to diagnose Head and Neck Squamous Cell Carcinoma (HNSCC) in 381 WSIs from 156 patients, affecting both the primary tumor and lymph node levels. The results demonstrated an accuracy of 84.8 ± 1.6%, sensitivity of 84.7 ± 2.2%, and specificity of 85.0 ± 2.2%.

Lopez-Janeiro et al. focused on salivary gland tumors and employed a tree model algorithm to determine the various histotypes of malignant tumors in 115 salivary gland samples, achieving an overall accuracy of 84.6%.

Zhou et al. developed a dual-modality optical imaging microscope that utilized machine learning algorithms to automatically detect laryngeal squamous cell carcinoma (SCC). They employed Random Forest, Gaussian naive Bayes, Support Vector Machine (SVM), and Logistic regression algorithms, with SVM yielding the highest accuracy.

He et al. conducted a study to evaluate a method for diagnosing laryngeal SCC. A total of 1228 patients underwent AI-aided endoscopy of the upper aerodigestive tract, resulting in 3458 pathological images. Suspicious laryngeal lesions were biopsied and histologically examined. The pathology images

were randomly divided into a training dataset, a validation dataset, and a testing dataset. The Inception V3 algorithm was employed, and the area under the curve (AUC) for the validation dataset was 0.994, while for the testing dataset, it was 0.981.

Current Challenges in Screening and Risk Assessment of Head and Neck Cancers

Despite the importance of screening and risk assessment in head and neck cancers, the current methods face several challenges. This section examines the limitations and complexities associated with traditional approaches, highlighting the need for more advanced techniques and tools, such as artificial intelligence (AI).

One of the primary challenges in head and neck cancer screening is the subjective nature of physical examination. Healthcare professionals rely on their visual inspection and palpation skills to identify suspicious lesions or abnormalities. However, the human eye and touch may miss subtle changes or early signs of cancer, especially in anatomically complex regions or when lesions are small or hidden. This subjectivity can lead to variability in interpretation among healthcare professionals, potentially compromising the accuracy and consistency of the screening process.

Moreover, patient-reported symptoms may not always be reliable indicators of head and neck cancers. Symptoms such as hoarseness, difficulty swallowing, or a persistent sore throat can be associated with various conditions, both benign and malignant. Additionally, patients may not always recognize or report these symptoms, especially in the early stages of the disease. Hence, relying solely on symptoms may result in delayed diagnosis and missed opportunities for early intervention.

The complexity of risk assessment in head and neck cancers poses another challenge. These cancers are influenced by a combination of genetic, environmental, and lifestyle factors. Determining an individual's risk accurately requires comprehensive evaluation and integration of various factors, such as tobacco and alcohol use, HPV infection status, occupational exposures, genetic predisposition, and family history. However, assessing and analyzing these multifactorial aspects can be complex and time-consuming, often requiring extensive data collection and expert interpretation.

Furthermore, access to head and neck cancer screening and risk assessment may be limited in certain regions, particularly in low-resource settings or areas with limited healthcare infrastructure. This can result in disparities in early detection and diagnosis, as well as hinder the implementation of preventive measures and appropriate management strategies.

To address these challenges, there is a growing need for more advanced and objective tools in head and neck cancer screening and risk assessment.

This is where artificial intelligence (AI) can play a transformative role. AI algorithms can analyze large amounts of data, detect patterns, and make accurate predictions, providing a more objective and standardized approach to screening and risk assessment.

AI-powered imaging analysis can assist in the detection and characterization of suspicious lesions in head and neck cancers. By analyzing medical images, such as CT scans, MRI, or PET scans, AI algorithms can identify abnormal features, assess their characteristics, and classify them as potentially malignant. This can aid in the early detection of lesions that may be missed by the human eye and improve the accuracy of diagnosis.

Additionally, AI-driven risk assessment models can integrate multiple data points, including clinical information, patient demographics, lifestyle factors, genetic data, and biomarkers. By processing and analyzing these data, AI algorithms can generate personalized risk profiles, enabling healthcare professionals to identify individuals at higher risk of developing head and neck cancers. This information can guide the implementation of targeted prevention strategies, regular surveillance protocols, and early intervention measures.

In conclusion, the current methods of head and neck cancer screening and risk assessment face challenges related to subjectivity, reliance on symptoms, complexity, and limited access. The integration of artificial intelligence can address these challenges by providing objective and accurate analysis of suspicious lesions, enhancing early detection, and enabling comprehensive risk assessment. AI algorithms have the potential to augment healthcare professionals' expertise, leading to improved outcomes in the screening and management of head and neck cancers.

Role of Artificial Intelligence in Head and Neck Cancer Screening

Artificial intelligence (AI) has emerged as a transformative technology in the field of medical imaging analysis, including the screening and diagnosis of head and neck cancers. This section focuses on the specific role of AI in head and neck cancer screening, particularly in the analysis of medical images such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans.

AI algorithms can analyze medical images with remarkable precision and speed, assisting healthcare professionals in detecting and characterizing suspicious lesions. By leveraging deep learning techniques, AI algorithms can learn from vast amounts of imaging data, identifying patterns and features that may be indicative of malignant or pre-malignant conditions.

In head and neck cancer screening, AI algorithms can analyze CT scans to identify and localize abnormalities such as tumors or suspicious nodules. AI can assist in segmenting and measuring lesions,

providing quantitative information that can aid in determining their size, shape, and growth patterns. This information is crucial for accurate diagnosis and treatment planning.

MRI is another imaging modality commonly used in the evaluation of head and neck cancers. AI algorithms can analyze MRI images to identify and characterize lesions, distinguishing between benign and malignant conditions. AI can assist in identifying subtle features and patterns that may not be apparent to the human eye, improving the detection rate and reducing the likelihood of false-negative results.

PET scans, which involve the injection of a radioactive tracer to visualize metabolic activity, are valuable in assessing the extent and spread of head and neck cancers. AI algorithms can analyze PET images to identify areas of increased uptake, indicating potential tumor locations and metastatic involvement. By precisely localizing and quantifying metabolic activity, AI can aid in treatment planning, monitoring response to therapy, and assessing disease progression.

The integration of AI into head and neck cancer screening workflows offers several advantages. First, AI algorithms can provide a consistent and standardized approach to image analysis, reducing interobserver variability and improving diagnostic accuracy. This is particularly valuable in regions where access to specialized healthcare professionals may be limited, as AI can assist in providing reliable

and timely interpretations.
Second, AI algorithms can analyze vast amounts of imaging data in a fraction of the time it would take for a human expert to review. This accelerated analysis can expedite the screening process, enabling prompt identification of suspicious lesions and facilitating early intervention.
Third, AI can serve as a powerful decision support tool for healthcare professionals. By providing quantitative measurements, risk stratification, and predictive analytics, AI can augment the expertise of radiologists and other specialists, empowering them to make informed clinical decisions and optimize patient management strategies.
However, it is important to note that AI is not meant to replace healthcare professionals but rather to augment their capabilities. The integration of AI into head and neck cancer screening requires a collaborative and interdisciplinary approach, combining the expertise of radiologists, oncologists, and AI specialists. The human interpretation and clinical judgment remain essential in the overall evaluation and management of patients.
In conclusion, AI has the potential to revolutionize head and neck cancer screening by providing objective and accurate analysis of medical images. AI algorithms can detect suspicious lesions, characterize their features, and assist in treatment planning. The integration of AI into screening workflows can enhance diagnostic accuracy, expedite the screening process, and empower

healthcare professionals with valuable decision support tools. By leveraging the capabilities of AI, we can improve early detection, optimize patient outcomes, and ultimately reduce the burden of head and neck cancers.

7- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF GYNECOLOGIC CANCERS

Introduction to Gynecologic Cancers

Gynecologic cancers encompass a group of malignancies that affect the female reproductive system, including the cervix, uterus, ovaries, fallopian tubes, vagina, and vulva. These cancers pose a significant health burden globally, with varying incidence rates and mortality rates across different regions. Early detection and accurate risk assessment are crucial for improving outcomes in gynecologic cancers. This section provides an overview of the different types of gynecologic cancers and their impact on women's health.

Gynecologic cancers can be broadly categorized into five main types: cervical cancer, uterine (endometrial) cancer, ovarian cancer, vulvar cancer, and vaginal cancer. Each type has unique risk factors, clinical presentations, and treatment approaches. Cervical cancer, for example, is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV), while uterine cancer is often associated with hormonal imbalances and obesity. Ovarian cancer is known for its insidious nature and is often diagnosed at advanced stages, making early detection particularly challenging. Vulvar and vaginal cancers are relatively rare but can have a significant impact on women's quality of life.

Gynecologic cancers can cause a range of symptoms, including abnormal vaginal bleeding, pelvic pain, changes in bowel or bladder habits, and unexplained weight loss. However, these symptoms are non-specific and can be caused by various other conditions. This emphasizes the need for effective screening and risk assessment methods to identify individuals at higher risk or with early signs of gynecologic cancers. Advances in artificial intelligence (AI) offer promising opportunities to enhance screening and risk assessment in gynecologic cancers by leveraging the power of data analysis and predictive modeling.

Current Challenges in Screening and Risk Assessment of Gynecologic Cancers

Screening and risk assessment for gynecologic cancers face several challenges that limit their effectiveness. This section explores the limitations and complexities associated with current approaches, highlighting the need for AI-based solutions in gynecologic cancer management.

One of the primary challenges is the lack of

accurate and reliable screening methods for certain gynecologic cancers. For instance, while cervical cancer screening using Pap tests and HPV testing has been highly effective, there is no widely accepted screening test for ovarian or uterine cancers. This results in delayed diagnosis and missed opportunities for early intervention.

Risk assessment in gynecologic cancers is also complex due to the interplay of various factors. Genetic predisposition, reproductive history, hormonal factors, obesity, and exposure to certain infections or medications can contribute to an individual's risk of developing gynecologic cancers. Integrating and analyzing these multifactorial aspects can be challenging, requiring comprehensive evaluation and expert interpretation.

Furthermore, the subjective nature of current screening methods, such as visual inspection and palpation, can lead to variability in interpretation among healthcare professionals. This subjectivity can affect the consistency and accuracy of screening, especially in cases where lesions or abnormalities are subtle or difficult to detect.

Access to gynecologic cancer screening and risk assessment is another issue, particularly in resource-limited settings or regions with limited healthcare infrastructure. Disparities in screening rates and access to preventive services contribute to disparities in cancer outcomes, highlighting the need for innovative and accessible solutions.

The integration of AI in screening and risk assessment of gynecologic cancers has the potential to address these challenges and improve patient care. AI algorithms can analyze complex datasets, identify patterns, and make accurate predictions, providing a more objective and standardized approach to screening and risk assessment.

Role of Artificial Intelligence in Gynecologic Cancer Screening

Artificial intelligence (AI) has emerged as a transformative technology in the field of medical imaging analysis, including gynecologic cancer screening. This section focuses on the specific role of AI in gynecologic cancer screening, particularly in the analysis of medical images and the development of predictive models.

AI algorithms can analyze medical images such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, aiding in the detection and characterization of gynecologic lesions. For example, in cervical cancer screening, AI algorithms can analyze cervical images to identify abnormal cells or lesions, assisting healthcare professionals in making accurate diagnoses.

In ovarian cancer, which often presents with non-specific symptoms and lacks effective screening tools, AI has shown promise in improving detection and risk assessment. AI algorithms can analyze ovarian ultrasound images, identifying patterns

and features associated with ovarian tumors. This can help differentiate between benign and malignant cysts, allowing for more accurate risk stratification and timely intervention.

AI can also play a role in the analysis of histopathological slides. By training on large datasets of digitized slides, AI algorithms can assist pathologists in identifying suspicious areas, quantifying cellular features, and predicting malignancy. This can improve the accuracy and efficiency of pathology assessments, contributing to more precise diagnosis and treatment decisions.

Potential Benefits and Challenges of AI in Gynecologic Cancer Screening

The integration of artificial intelligence (AI) in gynecologic cancer screening holds significant potential for improving patient outcomes and healthcare delivery. However, it is important to consider both the benefits and challenges associated with AI implementation in this context. This section explores the potential benefits and challenges of AI in gynecologic cancer screening.

Benefits of AI in Gynecologic Cancer Screening

Increased accuracy and sensitivity: AI algorithms have the potential to enhance the accuracy and sensitivity of gynecologic cancer screening. By analyzing large volumes of data and detecting subtle

patterns or abnormalities that may be missed by human observers, AI algorithms can improve the detection rate of early-stage cancers and reduce false-negative results.
Standardization and consistency: AI algorithms provide a standardized and consistent approach to screening and risk assessment. By reducing interobserver variability, AI can help ensure that all patients receive the same level of care, regardless of the expertise of the healthcare professional or the geographical location of the screening facility.
Efficient and timely screening: AI algorithms can analyze medical images and other data rapidly, significantly reducing the time required for screening and risk assessment. This increased efficiency can lead to timely identification of suspicious lesions, enabling earlier intervention and potentially improving patient outcomes.
Personalized risk assessment: AI algorithms can integrate and analyze multiple data sources, such as medical history, genetic information, and biomarkers, to provide personalized risk assessment for gynecologic cancers. By considering individual risk factors and generating risk scores or probabilities, AI can help tailor screening strategies and interventions to each patient's specific needs.

Challenges of AI in Gynecologic Cancer Screening

Data quality and availability: AI algorithms rely on large, high-quality datasets for training and

validation. However, obtaining such datasets for gynecologic cancer screening can be challenging. Some types of gynecologic cancers are relatively rare, and there may be variations in data collection protocols or imaging techniques across different healthcare institutions. Ensuring the availability and quality of diverse and representative datasets is crucial for developing robust and generalizable AI models.
Ethical and legal considerations: The use of AI in healthcare raises ethical and legal considerations. Patient privacy, data protection, and informed consent are important aspects to consider when implementing AI in gynecologic cancer screening. Healthcare organizations and policymakers must establish guidelines and regulations to ensure the responsible and ethical use of AI technologies.
Integration into clinical workflows: Integrating AI algorithms into existing clinical workflows can be a complex process. Healthcare professionals need to be trained on how to effectively use AI tools and interpret their outputs. Additionally, there may be challenges in seamlessly integrating AI systems with electronic health records and other healthcare IT infrastructure, requiring careful planning and coordination.
Overreliance on AI: While AI can enhance and augment the capabilities of healthcare professionals, it is important to avoid overreliance on AI algorithms. The human expertise and clinical judgment of healthcare professionals remain

essential in the overall evaluation and management of gynecologic cancers. AI should be viewed as a tool to support decision-making rather than a replacement for healthcare professionals.

In conclusion, the integration of AI in gynecologic cancer screening offers numerous potential benefits, including increased accuracy, standardization, efficiency, and personalized risk assessment. However, challenges related to data quality, ethical considerations, workflow integration, and maintaining the appropriate balance between AI and human expertise must be addressed. By carefully addressing these challenges and leveraging the strengths of AI, it is possible to harness its full potential and improve the early detection and management of gynecologic cancers.

8- ROLE OF ARTIFICIAL INTELLIGENCE IN SCREENING AND RISK ASSESSMENT OF OTHER CANCERS

Introduction to the Role of Artificial Intelligence in Screening and Risk Assessment of Leukemia

Leukemia is a type of cancer that affects the blood and bone marrow, and it can be challenging to diagnose and assess the risk associated with this disease. In recent years, artificial intelligence (AI) has emerged as a powerful tool in the field of cancer research and healthcare. This section provides an introduction to the role of AI in the screening and risk assessment of leukemia.

Leukemia is characterized by the abnormal growth of white blood cells in the body, which can lead to a range of symptoms and complications. The early detection of leukemia is crucial for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as blood tests and bone marrow biopsies, have limitations in terms of accuracy and efficiency.

AI offers the potential to enhance the screening and risk assessment of leukemia by leveraging

advanced machine learning algorithms and data analysis techniques. By analyzing large datasets of patient information, such as genetic profiles, medical records, and imaging data, AI algorithms can identify patterns and markers that may be indicative of leukemia. This can aid in the early detection and diagnosis of the disease, enabling timely interventions.

AI in Imaging and Diagnosis of Leukemia

Medical imaging plays a vital role in the diagnosis and monitoring of leukemia. This section explores the application of AI in imaging and diagnosis, highlighting the advancements and potential benefits in the field of leukemia.

AI algorithms can be trained on large datasets of imaging data, such as X-rays, computed tomography (CT) scans, and magnetic resonance imaging (MRI) scans, to identify characteristic features and patterns associated with leukemia. By analyzing these images, AI algorithms can assist radiologists in making accurate and timely diagnoses, reducing the potential for misdiagnosis or missed diagnoses.

Furthermore, AI can enhance the efficiency of image interpretation by automating certain tasks. For example, AI algorithms can segment and quantify abnormal cells or lesions in imaging data, providing valuable information for leukemia diagnosis and monitoring. This can save time for healthcare professionals and improve the overall workflow in cancer care.

AI in Risk Assessment and Prognosis of Leukemia

Assessing the risk and prognosis of leukemia is crucial for determining the most appropriate treatment strategies and predicting patient outcomes. This section discusses the role of AI in risk assessment and prognosis prediction in leukemia.

AI algorithms can integrate various patient data, including clinical information, genetic profiles, and treatment responses, to generate personalized risk scores or prognostic models. By analyzing these data, AI can identify specific biomarkers or genetic abnormalities associated with different subtypes of leukemia. This information can help healthcare professionals stratify patients into risk groups and guide treatment decisions, such as determining the need for more aggressive therapies or stem cell transplantation.

Moreover, AI can aid in long-term prognosis prediction by analyzing patient outcomes and treatment responses. By continuously analyzing and learning from real-world data, AI algorithms can refine and improve prognostic models, providing more accurate predictions of survival rates or disease progression. This can assist in developing tailored treatment plans and improving patient counseling and support.

Ethical Considerations and Future Challenges

As AI continues to advance in the field of leukemia screening and risk assessment, it is essential to address ethical considerations and anticipate future challenges. This section explores the ethical implications and potential challenges associated with the use of AI in leukemia care.

One of the main ethical considerations is the responsible use of patient data. AI algorithms rely on large datasets for training and validation, which can raise concerns about privacy, data protection, and consent. Ensuring proper safeguards and adhering to regulatory guidelines are crucial to maintain patient confidentiality and trust in AI systems.

Another challenge is the integration of AI algorithms into clinical practice. Healthcare professionals need to be trained in using and interpreting AI-generated results effectively. Additionally, there is a need for standardized guidelines and regulations to ensure the quality and reliability of AI systems in leukemia screening and risk assessment.

Furthermore, the cost and accessibility of AI technologies can be a barrier to widespread implementation. Ensuring equitable access to AI-based tools and addressing disparities in healthcare resources are important considerations for the successful integration of AI in leukemia care.

In conclusion, AI has the potential to revolutionize the screening and risk assessment of leukemia by leveraging advanced algorithms and data analysis techniques. From imaging and diagnosis to risk assessment and prognosis prediction, AI can enhance the accuracy and efficiency of leukemia care. However, ethical considerations and challenges must be addressed to ensure responsible and equitable use of AI in leukemia management.

Introduction to the Role of Artificial Intelligence in Screening and Risk Assessment of Bone Cancer

Bone cancer is a rare but serious condition that requires early detection and accurate risk assessment for effective treatment. Artificial intelligence (AI) has shown promise in various aspects of cancer care, including screening and risk assessment. In this section, we will explore the role of AI in the screening and risk assessment of bone cancer.

Bone cancer encompasses different types, such as osteosarcoma, chondrosarcoma, and Ewing sarcoma. Detecting bone cancer at an early stage can significantly improve patient outcomes. However, the diagnosis of bone cancer is often challenging due to its rarity and the complexity of interpreting imaging studies. AI has the potential to assist in the early detection and risk assessment of bone cancer by leveraging advanced algorithms and machine

learning techniques.

AI in Imaging and Diagnosis of Bone Cancer

Medical imaging plays a crucial role in the diagnosis and staging of bone cancer. AI algorithms can analyze large volumes of imaging data, including X-rays, computed tomography (CT) scans, and magnetic resonance imaging (MRI) scans, to aid in the detection and diagnosis of bone cancer.

AI can help radiologists by automatically identifying suspicious regions in images, such as abnormal bone lesions or tumors. By analyzing the characteristics and patterns of these lesions, AI algorithms can assist in distinguishing benign bone abnormalities from potentially cancerous ones. This can help in reducing false-negative or false-positive diagnoses, leading to more accurate and timely detection of bone cancer.

Moreover, AI algorithms can assist in the staging of bone cancer by analyzing imaging data and providing quantitative measurements. This can aid in determining the extent of tumor involvement, assessing metastatic spread, and guiding treatment decisions.

AI in Risk Assessment and Prognosis of Bone Cancer

Assessing the risk and prognosis of bone cancer is essential for developing appropriate treatment strategies and predicting patient outcomes. AI can play a valuable role in risk assessment and prognostic prediction in bone cancer.

By analyzing patient data, including clinical information, genetic profiles, and treatment responses, AI algorithms can identify specific biomarkers or genetic abnormalities associated with different subtypes of bone cancer. This information can assist in stratifying patients into risk groups, which can guide treatment decisions, such as the selection of surgical procedures, chemotherapy regimens, or targeted therapies.

AI can also aid in predicting the prognosis of bone cancer by analyzing patient outcomes and treatment responses. By continuously learning from real-world data, AI algorithms can refine and improve prognostic models, providing more accurate predictions of survival rates, disease recurrence, or progression. This information can help in tailoring treatment plans and providing patients with appropriate counseling and support.

Ethical Considerations and Future Challenges

As AI continues to evolve in the field of bone cancer screening and risk assessment, there are important ethical considerations and potential challenges to address. This section explores some of these considerations and challenges.

One ethical consideration is the responsible use of patient data. AI algorithms require access to large datasets for training and validation, which

raises concerns about privacy, data protection, and informed consent. Ensuring proper safeguards and adhering to regulatory guidelines are crucial to maintain patient confidentiality and trust in AI systems.

Another challenge is the integration of AI into clinical practice. Healthcare professionals need to be trained in using and interpreting AI-generated results effectively. Additionally, there is a need for standardized guidelines and regulations to ensure the quality and reliability of AI systems in bone cancer screening and risk assessment.

Furthermore, the cost and accessibility of AI technologies can be a barrier to widespread implementation. Ensuring equitable access to AI-based tools and addressing disparities in healthcare resources are important considerations for the successful integration of AI in bone cancer care.

In conclusion, AI has the potential to enhance the screening and risk assessment of bone cancer by leveraging advanced algorithms and machine learning techniques. From imaging and diagnosis to risk assessment and prognostic prediction, AI can improve the accuracy and effectiveness of bone cancer care. However, ethical considerations and challenges must be addressed to ensure responsible and equitable use of AI in bone cancer management.

REFERENCES

1 .Aboumerhi K, Güemes A, Liu H, Tenore F, Etienne-Cummings R. Neuromorphic applications in medicine. J Neural Eng. 2023;20(4). doi:10.1088/1741-2552/aceca3.

2 .Abreu-Gomez J, Lim C, Haider MA. Contemporary Approach to Prostate Imaging and Data Reporting System Score 3 Lesions. Radiol Clin North Am. 2024;62(1):37-51. doi:10.1016/j.rcl.2023.06.008.

3 .Adams SJ, Mikhael P, Wohlwend J, Barzilay R, Sequist LV, Fintelmann FJ. Artificial Intelligence and Machine Learning in Lung Cancer Screening. Thorac Surg Clin. 2023;33(4):401-9. doi:10.1016/j.thorsurg.2023.03.001.

4 .Ahamed MF, Hossain MM, Nahiduzzaman M, Islam MR, Islam MR, Ahsan M et al. A review on brain tumor segmentation based on deep learning methods with federated learning techniques. Comput Med Imaging Graph. 2023;110:102313. doi:10.1016/j.compmedimag.2023.102313.

5 .Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI et al. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. J Breast Cancer. 2023;26(5):405-35. doi:10.4048/jbc.2023.26.e45.

6 .Al-Rajab M, Lu J, Xu Q, Kentour M, Sawsa A, Shuweikeh E et al. A hybrid machine learning feature selection model-HMLFSM to enhance gene classification applied to multiple colon cancers dataset. PLoS One. 2023;18(11):e0286791. doi:10.1371/journal.pone.0286791.

7 .Al-Thelaya K, Gilal NU, Alzubaidi M, Majeed F, Agus M, Schneider J et al. Applications of discriminative and deep learning feature extraction methods for whole slide image analysis: A survey. J Pathol Inform. 2023;14:100335. doi:10.1016/j.jpi.2023.100335.

8 .Alajaji SA, Khoury ZH, Elgharib M, Saeed M, Ahmed ARH, Khan MB et al. Generative Adversarial Networks in Digital Histopathology: Current Applications, Limitations, Ethical Considerations, and Future Directions. Mod Pathol. 2023;37(1):100369. doi:10.1016/j.modpat.2023.100369.

9 .Alhajahjeh A, Nazha A. Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2023. doi:10.1007/s11899-023-00716-5.

10 .Ali H, Mohsen F, Shah Z. Improving diagnosis and prognosis of lung cancer using vision transformers: a scoping review. BMC Med Imaging. 2023;23(1):129. doi:10.1186/s12880-023-01098-z.

11 .Ali H, Qureshi R, Shah Z. Artificial Intelligence-Based Methods for Integrating Local and Global Features for Brain Cancer Imaging: Scoping Review. JMIR Med Inform. 2023;11:e47445. doi:10.2196/47445.

12 .Altuhaifa FA, Win KT, Su G. Predicting lung cancer survival based on clinical data using machine learning: A review.

Comput Biol Med. 2023;165:107338. doi:10.1016/j.compbiomed.2023.107338.
13 .Ansari MY, Qaraqe M, Righetti R, Serpedin E, Qaraqe K. Unveiling the future of breast cancer assessment: a critical review on generative adversarial networks in elastography ultrasound. Front Oncol. 2023;13:1282536. doi:10.3389/fonc.2023.1282536.
14 .Aquino IMC, Pascut D. Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care. Ann Hepatol. 2023;29(2):101176. doi:10.1016/j.aohep.2023.101176.
15 .Arif AA, Jiang SX, Byrne MF. Artificial intelligence in endoscopy: Overview, applications, and future directions. Saudi J Gastroenterol. 2023;29(5):269-77. doi:10.4103/sjg.sjg_286_23.
16 .Arıbal E. Future of Breast Radiology. Eur J Breast Health. 2023;19(4):262-6. doi:10.4274/ejbh.galenos.2023.2023-8-3.
17 .Arponen O, Wodtke P, Gallagher FA, Woitek R. Hyperpolarised (13)C-MRI using (13)C-pyruvate in breast cancer: A review. Eur J Radiol. 2023;167:111058. doi:10.1016/j.ejrad.2023.111058.
18 .Aswathy R, Sumathi S. Defining new biomarkers for overcoming therapeutical resistance in cervical cancer using lncRNA. Mol Biol Rep. 2023;50(12):10445-60. doi:10.1007/s11033-023-08864-w.
19 .Avella P, Cappuccio M, Cappuccio T, Rotondo M,

Fumarulo D, Guerra G et al. Artificial Intelligence to Early Predict Liver Metastases in Patients with Colorectal Cancer: Current Status and Future Prospectives. Life (Basel). 2023;13(10). doi:10.3390/life13102027.
20 .Azadi Moghadam P, Bashashati A, Goldenberg SL. Artificial Intelligence and Pathomics: Prostate Cancer. Urol Clin North Am. 2024;51(1):15-26. doi:10.1016/j.ucl.2023.06.001.
21 .Balma M, Laudicella R, Gallio E, Gusella S, Lorenzon L, Peano S et al. Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs). Life (Basel). 2023;13(8). doi:10.3390/life13081647.
22 .Balsano C, Burra P, Duvoux C, Alisi A, Piscaglia F, Gerussi A. Artificial Intelligence and liver: Opportunities and barriers. Dig Liver Dis. 2023;55(11):1455-61. doi:10.1016/j.dld.2023.08.048.
23 .Barat M, Pellat A, Hoeffel C, Dohan A, Coriat R, Fishman EK et al. CT and MRI of abdominal cancers: current trends and perspectives in the era of radiomics and artificial intelligence. Jpn J Radiol. 2023. doi:10.1007/s11604-023-01504-0.
24 .Barrett T, Lee KL, de Rooij M, Giganti F. Update on Optimization of Prostate MR Imaging Technique and Image Quality. Radiol Clin North Am. 2024;62(1):1-15. doi:10.1016/j.rcl.2023.06.006.
25 .Bazarkin A, Morozov A, Androsov A, Fajkovic H, Rivas JG, Singla N et al. Assessment of Prostate and

Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review. Curr Urol Rep. 2023. doi:10.1007/s11934-023-01193-2.
26 .Beniwal SS, Lamo P, Kaushik A, Lorenzo-Villegas DL, Liu Y, MohanaSundaram A. Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics. Biosensors (Basel). 2023;13(10). doi:10.3390/bios13100926.
27 .Bhattacharya K, Rastogi S, Mahajan A. Post-treatment imaging of gliomas: challenging the existing dogmas. Clin Radiol. 2023. doi:10.1016/j.crad.2023.11.017.
28 .Biamonte P, D'Amico F, Fasulo E, Barà R, Bernardi F, Allocca M et al. New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients. Biomedicines. 2023;11(8). doi:10.3390/biomedicines11082139.
29 .Bojunga J, Trimboli P. Thyroid ultrasound and its ancillary techniques. Rev Endocr Metab Disord. 2023. doi:10.1007/s11154-023-09841-1.
30 .Bousis D, Verras GI, Bouchagier K, Antzoulas A, Panagiotopoulos I, Katinioti A et al. The role of deep learning in diagnosing colorectal cancer. Prz Gastroenterol. 2023;18(3):266-73. doi:10.5114/pg.2023.129494.
31 .Brancaccio G, Balato A, Malvehy J, Puig S, Argenziano G, Kittler H. Artificial Intelligence in Skin Cancer Diagnosis: A Reality Check. J Invest Dermatol. 2023. doi:10.1016/j.jid.2023.10.004.
32 .Breen J, Allen K, Zucker K, Adusumilli P, Scarsbrook A, Hall G et al. Artificial intelligence

in ovarian cancer histopathology: a systematic review. NPJ Precis Oncol. 2023;7(1):83. doi:10.1038/s41698-023-00432-6.
33 .Campana A, Gandomkar Z, Giannotti N, Reed W. The use of radiomics in magnetic resonance imaging for the pre-treatment characterisation of breast cancers: A scoping review. J Med Radiat Sci. 2023;70(4):462-78. doi:10.1002/jmrs.709.
34 .Cellina M, Cacioppa LM, Cè M, Chiarpenello V, Costa M, Vincenzo Z et al. Artificial Intelligence in Lung Cancer Screening: The Future Is Now. Cancers (Basel). 2023;15(17). doi:10.3390/cancers15174344.
35 .Chaddad A, Tan G, Liang X, Hassan L, Rathore S, Desrosiers C et al. Advancements in MRI-Based Radiomics and Artificial Intelligence for Prostate Cancer: A Comprehensive Review and Future Prospects. Cancers (Basel). 2023;15(15). doi:10.3390/cancers15153839.
36 .Chalamalasetti SD, Tamrakar S, Doshi P, Vora NN, Karrothu V, Pathe AR. Gender Equality Trends of First Authors in Publications of Artificial Intelligence and Thyroid. Cureus. 2023;15(9):e45820. doi:10.7759/cureus.45820.
37 .Champendal M, Müller H, Prior JO, Dos Reis CS. A scoping review of interpretability and explainability concerning artificial intelligence methods in medical imaging. Eur J Radiol. 2023;169:111159. doi:10.1016/j.ejrad.2023.111159.
38 .Chandrabhatla AS, Horgan TM, Cotton CC, Ambati NK, Shildkrot YE. Clinical Applications of

Machine Learning in the Management of Intraocular Cancers: A Narrative Review. Invest Ophthalmol Vis Sci. 2023;64(10):29. doi:10.1167/iovs.64.10.29.
39 .Chen X, Liu X, Wu Y, Wang Z, Wang SH. Research related to the diagnosis of prostate cancer based on machine learning medical images: A review. Int J Med Inform. 2024;181:105279. doi:10.1016/j.ijmedinf.2023.105279.
40 .Choi S, Kim S. Artificial Intelligence in the Pathology of Gastric Cancer. J Gastric Cancer. 2023;23(3):410-27. doi:10.5230/jgc.2023.23.e25.
41 .Crombé A, Spinnato P, Italiano A, Brisse HJ, Feydy A, Fadli D et al. Radiomics and artificial intelligence for soft-tissue sarcomas: Current status and perspectives. Diagn Interv Imaging. 2023;104(12):567-83. doi:10.1016/j.diii.2023.09.005.
42 .Cui S, Traverso A, Niraula D, Zou J, Luo Y, Owen D et al. Interpretable artificial intelligence in radiology and radiation oncology. Br J Radiol. 2023;96(1150):20230142. doi:10.1259/bjr.20230142.
43 .Danishuddin, Khan S, Kim JJ. From cancer big data to treatment: Artificial intelligence in cancer research. J Gene Med. 2023:e3629. doi:10.1002/jgm.3629.
44 .Davri A, Birbas E, Kanavos T, Ntritsos G, Giannakeas N, Tzallas AT et al. Deep Learning for Lung Cancer Diagnosis, Prognosis and Prediction Using Histological and Cytological Images: A Systematic Review. Cancers (Basel). 2023;15(15).

doi:10.3390/cancers15153981.
45 .de Chauveron J, Unger M, Lescaille G, Wendling L, Kurtz C, Rochefort J. Artificial intelligence for oral squamous cell carcinoma detection based on oral photographs: A comprehensive literature review. Cancer Med. 2024. doi:10.1002/cam4.6822.
46 .Debelee TG. Skin Lesion Classification and Detection Using Machine Learning Techniques: A Systematic Review. Diagnostics (Basel). 2023;13(19). doi:10.3390/diagnostics13193147.
47 .Deng J, Zhang W, Xu M, Zhou J. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy. Abdom Radiol (NY). 2023;48(12):3661-76. doi:10.1007/s00261-023-04046-1.
48 .Dholariya S, Singh RD, Sonagra A, Yadav D, Vajaria BN, Parchwani D. Integrating Cutting-Edge Methods to Oral Cancer Screening, Analysis, and Prognosis. Crit Rev Oncog. 2023;28(2):11-44. doi:10.1615/CritRevOncog.2023047772.
49 .Dhopte A, Bagde H. Smart Smile: Revolutionizing Dentistry With Artificial Intelligence. Cureus. 2023;15(6):e41227. doi:10.7759/cureus.41227.
50 .Dong X, Chen G, Zhu Y, Ma B, Ban X, Wu N et al. Artificial intelligence in skeletal metastasis imaging. Comput Struct Biotechnol J. 2024;23:157-64. doi:10.1016/j.csbj.2023.11.007.
51 .Dornblaser D, Young S, Shaukat A. Colon polyps: updates in classification and management. Curr Opin Gastroenterol. 2024;40(1):14-20. doi:10.1097/mog.0000000000000988.

52 .El Haji H, Souadka A, Patel BN, Sbihi N, Ramasamy G, Patel BK et al. Evolution of Breast Cancer Recurrence Risk Prediction: A Systematic Review of Statistical and Machine Learning-Based Models. JCO Clin Cancer Inform. 2023;7:e2300049. doi:10.1200/cci.23.00049.
53 .El Naqa I, Karolak A, Luo Y, Folio L, Tarhini AA, Rollison D et al. Translation of AI into oncology clinical practice. Oncogene. 2023;42(42):3089-97. doi:10.1038/s41388-023-02826-z.
54 .El Zoghbi M, Shaukat A, Hassan C, Anderson JC, Repici A, Gross SA. Artificial Intelligence-Assisted Optical Diagnosis: A Comprehensive Review of Its Role in Leave-In-Situ and Resect-and-Discard Strategies in Colonoscopy. Clin Transl Gastroenterol. 2023;14(10):e00640. doi:10.14309/ctg.0000000000000640.
55 .Elhadary M, Elshoeibi AM, Badr A, Elsayed B, Metwally O, Elshoeibi AM et al. Revolutionizing chronic lymphocytic leukemia diagnosis: A deep dive into the diverse applications of machine learning. Blood Rev. 2023;62:101134. doi:10.1016/j.blre.2023.101134.
56 .Fallahpoor M, Chakraborty S, Pradhan B, Faust O, Barua PD, Chegeni H et al. Deep learning techniques in PET/CT imaging: A comprehensive review from sinogram to image space. Comput Methods Programs Biomed. 2024;243:107880. doi:10.1016/j.cmpb.2023.107880.
57 .Fawaz A, Ferraresi A, Isidoro C. Systems Biology in Cancer Diagnosis Integrating Omics

Technologies and Artificial Intelligence to Support Physician Decision Making. J Pers Med. 2023;13(11). doi:10.3390/jpm13111590.
58 .Feng J, Yang K, Liu X, Song M, Zhan P, Zhang M et al. Machine learning: a powerful tool for identifying key microbial agents associated with specific cancer types. PeerJ. 2023;11:e16304. doi:10.7717/peerj.16304.
59 .Feng S, Wang J, Wang L, Qiu Q, Chen D, Su H et al. Current Status and Analysis of Machine Learning in Hepatocellular Carcinoma. J Clin Transl Hepatol. 2023;11(5):1184-91. doi:10.14218/jcth.2022.00077s.
60 .Franco-Moreno A, Madroñal-Cerezo E, Muñoz-Rivas N, Torres-Macho J, Ruiz-Giardín JM, Ancos-Aracil CL. Prediction of Venous Thromboembolism in Patients With Cancer Using Machine Learning Approaches: A Systematic Review and Meta-Analysis. JCO Clin Cancer Inform. 2023;7:e2300060. doi:10.1200/cci.23.00060.
61 .Froń A, Semianiuk A, Lazuk U, Ptaszkowski K, Siennicka A, Lemiński A et al. Artificial Intelligence in Urooncology: What We Have and What We Expect. Cancers (Basel). 2023;15(17). doi:10.3390/cancers15174282.
62 .Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M et al. Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas. Cancers (Basel). 2023;15(18). doi:10.3390/cancers15184666.

63 .Galati JS, Lin K, Gross SA. Recent advances in devices and technologies that might prove revolutionary for colonoscopy procedures. Expert Rev Med Devices. 2023;20(12):1087-103. doi:10.1080/17434440.2023.2280773.
64 .Gallos IK, Tryfonopoulos D, Shani G, Amditis A, Haick H, Dionysiou DD. Advancing Colorectal Cancer Diagnosis with AI-Powered Breathomics: Navigating Challenges and Future Directions. Diagnostics (Basel). 2023;13(24). doi:10.3390/diagnostics13243673.
65 .Gandhi Z, Gurram P, Amgai B, Lekkala SP, Lokhandwala A, Manne S et al. Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes. Cancers (Basel). 2023;15(21). doi:10.3390/cancers15215236.
66 .Gao Y, Lin J, Zhou Y, Lin R. The application of traditional machine learning and deep learning techniques in mammography: a review. Front Oncol. 2023;13:1213045. doi:10.3389/fonc.2023.1213045.
67 .Garg P, Mohanty A, Ramisetty S, Kulkarni P, Horne D, Pisick E et al. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189026. doi:10.1016/j.bbcan.2023.189026.
68 .Ge H, Li L, Zhang D, Ma F. Applications of digital Medicine in oncology: Prospects and challenges. Cancer Innov. 2022;1(4):285-92. doi:10.1002/cai2.37.

69 .Geaney A, O'Reilly P, Maxwell P, James JA, McArt D, Salto-Tellez M. Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption. Oncogene. 2023;42(48):3545-55. doi:10.1038/s41388-023-02857-6.
70 .Gelikman DG, Rais-Bahrami S, Pinto PA, Turkbey B. AI-powered radiomics: revolutionizing detection of urologic malignancies. Curr Opin Urol. 2024;34(1):1-7. doi:10.1097/mou.0000000000001144.
71 .George G, Russell B, Rigg A, Coolen ACC, Van Hemelrijck M. Real World Data Studies of Antineoplastic Drugs: How Can They Be Improved to Steer Everyday Use in the Clinic? Pragmat Obs Res. 2023;14:95-100. doi:10.2147/por.S395959.
72 .Gimeno-García AZ, Benítez-Zafra F, Nicolás-Pérez D, Hernández-Guerra M. Colon Bowel Preparation in the Era of Artificial Intelligence: Is There Potential for Enhancing Colon Bowel Cleansing? Medicina (Kaunas). 2023;59(10). doi:10.3390/medicina59101834.
73 .Gonzalez R, Nejat P, Saha A, Campbell CJV, Norgan AP, Lokker C. Performance of externally validated machine learning models based on histopathology images for the diagnosis, classification, prognosis, or treatment outcome prediction in female breast cancer: A systematic review. J Pathol Inform. 2024;15:100348. doi:10.1016/j.jpi.2023.100348.
74 .Grandi A, Bertoglio L, Lepidi S, Kölbel T, Mani K,

Budtz-Lilly J et al. Risk Prediction Models for Peri-Operative Mortality in Patients Undergoing Major Vascular Surgery with Particular Focus on Ruptured Abdominal Aortic Aneurysms: A Scoping Review. J Clin Med. 2023;12(17). doi:10.3390/jcm12175505.
75 .Guljaš S, Dupan Krivdić Z, Drežnjak Madunić M, Šambić Penc M, Pavlović O, Krajina V et al. Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate-Unnecessary or Underutilised? A Narrative Review. Diagnostics (Basel). 2023;13(22). doi:10.3390/diagnostics13223488.
76 .Hamilton S, Kingston BR. Applying artificial intelligence and computational modeling to nanomedicine. Curr Opin Biotechnol. 2023;85:103043. doi:10.1016/j.copbio.2023.103043.
77 .Harrison P, Hasan R, Park K. State-of-the-Art of Breast Cancer Diagnosis in Medical Images via Convolutional Neural Networks (CNNs). J Healthc Inform Res. 2023;7(4):387-432. doi:10.1007/s41666-023-00144-3.
78 .Hassan C, Spadaccini M, Mori Y, Foroutan F, Facciorusso A, Gkolfakis P et al. Real-Time Computer-Aided Detection of Colorectal Neoplasia During Colonoscopy : A Systematic Review and Meta-analysis. Ann Intern Med. 2023;176(9):1209-20. doi:10.7326/m22-3678.
79 .Hatamikia S, Nougaret S, Panico C, Avesani G, Nero C, Boldrini L et al. Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers. Eur Radiol Exp. 2023;7(1):50.

doi:10.1186/s41747-023-00364-7.
80 .Haydel JM, Xu AA, Mansour NM. High volume, low volume, or pills, which way should we go? a review of bowel preparation for colonoscopy. Curr Opin Gastroenterol. 2024;40(1):21-6. doi:10.1097/mog.0000000000000983.
81 .He M, Cao Y, Chi C, Yang X, Ramin R, Wang S et al. Research progress on deep learning in magnetic resonance imaging-based diagnosis and treatment of prostate cancer: a review on the current status and perspectives. Front Oncol. 2023;13:1189370. doi:10.3389/fonc.2023.1189370.
82 .Hegazi M, Taverna G, Grizzi F. Is Artificial Intelligence the Key to Revolutionizing Benign Prostatic Hyperplasia Diagnosis and Management? Arch Esp Urol. 2023;76(9):643-56. doi:10.56434/j.arch.esp.urol.20237609.79.
83 .Higgins H, Nakhla A, Lotfalla A, Khalil D, Doshi P, Thakkar V et al. Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma. Diagnostics (Basel). 2023;13(22). doi:10.3390/diagnostics13223483.
84 .Huang J, Fan X, Liu W. Applications and Prospects of Artificial Intelligence-Assisted Endoscopic Ultrasound in Digestive System Diseases. Diagnostics (Basel). 2023;13(17). doi:10.3390/diagnostics13172815.
85 .Huang S, Xu JT, Yang M. Review: Predictive approaches to breast cancer risk. Heliyon. 2023;9(11):e21344. doi:10.1016/

j.heliyon.2023.e21344.
86 .Iannantuono GM, Bracken-Clarke D, Floudas CS, Roselli M, Gulley JL, Karzai F. Applications of large language models in cancer care: current evidence and future perspectives. Front Oncol. 2023;13:1268915. doi:10.3389/fonc.2023.1268915.
87 .Ikeda A, Nosato H. Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours. Curr Opin Urol. 2024;34(1):27-31. doi:10.1097/mou.0000000000001135.
88 .Ishikawa T, Yamao K, Mizutani Y, Iida T, Kawashima H. Cutting edge of endoscopic ultrasound-guided fine-needle aspiration for solid pancreatic lesions. J Med Ultrason (2001). 2023. doi:10.1007/s10396-023-01375-y.
89 .Ivanova E, Fayzullin A, Grinin V, Ermilov D, Arutyunyan A, Timashev P et al. Empowering Renal Cancer Management with AI and Digital Pathology: Pathology, Diagnostics and Prognosis. Biomedicines. 2023;11(11). doi:10.3390/biomedicines11112875.
90 .Ivanova M, Porta FM, D'Ercole M, Pescia C, Sajjadi E, Cursano G et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2023. doi:10.1007/s00428-023-03656-w.
91 .Jafrasteh F, Farmani A, Mohamadi J. Meticulous research for design of plasmonics

sensors for cancer detection and food contaminants analysis via machine learning and artificial intelligence. Sci Rep. 2023;13(1):15349. doi:10.1038/s41598-023-42699-6.
92 .Jha AK, Mithun S, Sherkhane UB, Dwivedi P, Puts S, Osong B et al. Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology. Explor Target Antitumor Ther. 2023;4(4):569-82. doi:10.37349/etat.2023.00153.
93 .Jiang J, Chao WL, Cao T, Culp S, Napoléon B, El-Dika S et al. Improving Pancreatic Cyst Management: Artificial Intelligence-Powered Prediction of Advanced Neoplasms through Endoscopic Ultrasound-Guided Confocal Endomicroscopy. Biomimetics (Basel). 2023;8(6). doi:10.3390/biomimetics8060496.
94 .Jiang X, Hu Z, Wang S, Zhang Y. Deep Learning for Medical Image-Based Cancer Diagnosis. Cancers (Basel). 2023;15(14). doi:10.3390/cancers15143608.
95 .Jiang Y, Wang C, Zhou S. Artificial intelligence-based risk stratification, accurate diagnosis and treatment prediction in gynecologic oncology. Semin Cancer Biol. 2023;96:82-99. doi:10.1016/j.semcancer.2023.09.005.
96 .Jiang Y, Wang K, Wang YR, Xiang YJ, Liu ZH, Feng JK et al. Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence. Technol Cancer Res Treat. 2023;22:15330338231212726.

doi:10.1177/15330338231212726.
97 .Jin KW, Li Q, Xie Y, Xiao G. Artificial intelligence in mental healthcare: an overview and future perspectives. Br J Radiol. 2023;96(1150):20230213. doi:10.1259/bjr.20230213.
98 .Jing Y, Li C, Du T, Jiang T, Sun H, Yang J et al. A comprehensive survey of intestine histopathological image analysis using machine vision approaches. Comput Biol Med. 2023;165:107388. doi:10.1016/j.compbiomed.2023.107388.
99 .Kaifi R. A Review of Recent Advances in Brain Tumor Diagnosis Based on AI-Based Classification. Diagnostics (Basel). 2023;13(18). doi:10.3390/diagnostics13183007.
100 .Kalidindi S, Gandhi S. Workforce Crisis in Radiology in the UK and the Strategies to Deal With It: Is Artificial Intelligence the Saviour? Cureus. 2023;15(8):e43866. doi:10.7759/cureus.43866.
101 .Kaneko M, Magoulianitis V, Ramacciotti LS, Raman A, Paralkar D, Chen A et al. The Novel Green Learning Artificial Intelligence for Prostate Cancer Imaging: A Balanced Alternative to Deep Learning and Radiomics. Urol Clin North Am. 2024;51(1):1-13. doi:10.1016/j.ucl.2023.08.001.
102 .Kataoka M, Honda M, Sagawa H, Ohashi A, Sakaguchi R, Hashimoto H et al. Ultrafast Dynamic Contrast-Enhanced MRI of the Breast: From Theory to Practice. J Magn Reson Imaging. 2023. doi:10.1002/jmri.29082.
103 .Khan MJ, Singh AK, Sultana R, Singh PP,

Khan A, Saxena S. Breast cancer: A comparative review for breast cancer detection using machine learning techniques. Cell Biochem Funct. 2023;41(8):996-1007. doi:10.1002/cbf.3868.
104 .Khattar H, Goel R, Kumar P. Artificial Intelligence in Gynaecological Malignancies: Perspectives of a Clinical Oncologist. Cureus. 2023;15(9):e45660. doi:10.7759/cureus.45660.
105 .Khene ZE, Kammerer-Jacquet SF, Bigot P, Rabilloud N, Albiges L, Margulis V et al. Clinical Application of Digital and Computational Pathology in Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2023. doi:10.1016/j.euo.2023.10.018.
106 .Khoraminia F, Fuster S, Kanwal N, Olislagers M, Engan K, van Leenders G et al. Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review. Cancers (Basel). 2023;15(18). doi:10.3390/cancers15184518.
107 .Kim KW, Huh J, Urooj B, Lee J, Lee J, Lee IS et al. Artificial Intelligence in Gastric Cancer Imaging With Emphasis on Diagnostic Imaging and Body Morphometry. J Gastric Cancer. 2023;23(3):388-99. doi:10.5230/jgc.2023.23.e30.
108 .Klang E, Sourosh A, Nadkarni GN, Sharif K, Lahat A. Deep Learning and Gastric Cancer: Systematic Review of AI-Assisted Endoscopy. Diagnostics (Basel). 2023;13(24). doi:10.3390/diagnostics13243613.
109 .Knudsen JE, Rich JM, Ma R. Artificial Intelligence in Pathomics and Genomics of Renal Cell Carcinoma. Urol Clin North Am.

2024;51(1):47-62. doi:10.1016/j.ucl.2023.06.002.
110 .Kumar Barik A, Mathew C, Sanoop PM, John RV, Adigal SS, Bhat S et al. Protein profile pattern analysis: A multifarious, in vitro diagnosis technique for universal screening. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1232:123944. doi:10.1016/j.jchromb.2023.123944.
111 .Kumar V, Gaddam M, Moustafa A, Iqbal R, Gala D, Shah M et al. The Utility of Artificial Intelligence in the Diagnosis and Management of Pancreatic Cancer. Cureus. 2023;15(11):e49560. doi:10.7759/cureus.49560.
112 .Lai B, Fu J, Zhang Q, Deng N, Jiang Q, Peng J. Artificial intelligence in cancer pathology: Challenge to meet increasing demands of precision medicine. Int J Oncol. 2023;63(3). doi:10.3892/ijo.2023.5555.
113 .Lam S, Bai C, Baldwin DR, Chen Y, Connolly C, de Koning H et al. Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2023. doi:10.1016/j.jtho.2023.07.019.
114 .Laurie MA, Zhou SR, Islam MT, Shkolyar E, Xing L, Liao JC. Bladder Cancer and Artificial Intelligence: Emerging Applications. Urol Clin North Am. 2024;51(1):63-75. doi:10.1016/j.ucl.2023.07.002.
115 .Lebrun L, Salmon I. Pathology and new insights in thyroid neoplasms in the 2022 WHO classification. Curr Opin Oncol. 2024;36(1):13-21.

doi:10.1097/cco.0000000000001012.
116 .Lee J, Lee H, Chung JW. The Role of Artificial Intelligence in Gastric Cancer: Surgical and Therapeutic Perspectives: A Comprehensive Review. J Gastric Cancer. 2023;23(3):375-87. doi:10.5230/jgc.2023.23.e31.
117 .Lee YM, Lee B, Cho NH, Park JH. Beyond the Microscope: A Technological Overture for Cervical Cancer Detection. Diagnostics (Basel). 2023;13(19). doi:10.3390/diagnostics13193079.
118 .Leśniewska M, Patryn R, Kopystecka A, Kozioł I, Budzyńska J. Third Eye? The Assistance of Artificial Intelligence (AI) in the Endoscopy of Gastrointestinal Neoplasms. J Clin Med. 2023;12(21). doi:10.3390/jcm12216721.
119 .Li JW, Sheng DL, Chen JG, You C, Liu S, Xu HX et al. Artificial intelligence in breast imaging: potentials and challenges. Phys Med Biol. 2023;68(23). doi:10.1088/1361-6560/acfade.
120 .Li Y, Gao W, Luan Z, Zhou Z, Li J. The Impact of Chat Generative Pre-trained Transformer (ChatGPT) on Oncology: Application, Expectations, and Future Prospects. Cureus. 2023;15(11):e48670. doi:10.7759/cureus.48670.
121 .Lin G, Wang X, Ye H, Cao W. Radiomic Models Predict Tumor Microenvironment Using Artificial Intelligence-the Novel Biomarkers in Breast Cancer Immune Microenvironment. Technol Cancer Res Treat. 2023;22:15330338231218227. doi:10.1177/15330338231218227.
122 .Liu P, Sun Y, Zhao X, Yan Y. Deep

learning algorithm performance in contouring head and neck organs at risk: a systematic review and single-arm meta-analysis. Biomed Eng Online. 2023;22(1):104. doi:10.1186/s12938-023-01159-y.
123 .Liu W, Choi SJ, George D, Li L, Zhong Z, Zhang R et al. Untethered shape-changing devices in the gastrointestinal tract. Expert Opin Drug Deliv. 2023;20(12):1801-22. doi:10.1080/17425247.2023.2291450.
124 .Liu X, Shi J, Li Z, Huang Y, Zhang Z, Zhang C. The Present and Future of Artificial Intelligence in Urological Cancer. J Clin Med. 2023;12(15). doi:10.3390/jcm12154995.
125 .Liu Y, Wu M. Deep learning in precision medicine and focus on glioma. Bioeng Transl Med. 2023;8(5):e10553. doi:10.1002/btm2.10553.
126 .Liu YP, Yang WT, Bu H. [The trend of accurate pathology diagnosis of breast cancer]. Zhonghua Bing Li Xue Za Zhi. 2023;52(9):885-90. doi:10.3760/cma.j.cn112151-20230727-00030.
127 .Logan J, Kennedy PJ, Catchpoole D. A review of the machine learning datasets in mammography, their adherence to the FAIR principles and the outlook for the future. Sci Data. 2023;10(1):595. doi:10.1038/s41597-023-02430-6.
128 .Lokaj B, Pugliese MT, Kinkel K, Lovis C, Schmid J. Barriers and facilitators of artificial intelligence conception and implementation for breast imaging diagnosis in clinical practice: a scoping review. Eur Radiol. 2023. doi:10.1007/s00330-023-10181-6.
129 .Lorkowski SW, Dermawan JK, Rubin BP. The

practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review. Virchows Arch. 2023. doi:10.1007/s00428-023-03708-1.
130 .M SA, Al-Musawi SG, Al-Alwany AA, Uinarni H, Rasulova I, Rodrigues P et al. Artificial intelligence in cancer diagnosis: Opportunities and challenges. Pathol Res Pract. 2023;253:154996. doi:10.1016/j.prp.2023.154996.
131 .Ma T, Wang H, Ye Z. Artificial intelligence applications in computed tomography in gastric cancer: a narrative review. Transl Cancer Res. 2023;12(9):2379-92. doi:10.21037/tcr-23-201.
132 .Maccioni F, Busato L, Valenti A, Cardaccio S, Longhi A, Catalano C. Magnetic Resonance Imaging of the Gastrointestinal Tract: Current Role, Recent Advancements and Future Prospectives. Diagnostics (Basel). 2023;13(14). doi:10.3390/diagnostics13142410.
133 .Mainta IC, Sfakianaki I, Shiri I, Botsikas D, Garibotto V. The Clinical Added Value of Breast Cancer Imaging Using Hybrid PET/MR Imaging. Magn Reson Imaging Clin N Am. 2023;31(4):565-77. doi:10.1016/j.mric.2023.06.007.
134 .Malik S, Zaheer S. ChatGPT as an aid for pathological diagnosis of cancer. Pathol Res Pract. 2023;253:154989. doi:10.1016/j.prp.2023.154989.
135 .Marchegiani F, Siragusa L, Zadoroznyj A, Laterza V, Mangana O, Schena CA et al. New Robotic Platforms in General Surgery: What's the Current Clinical Scenario? Medicina (Kaunas). 2023;59(7).

doi:10.3390/medicina59071264.
136 .Mariano L, Nicosia L, Pupo D, Olivieri AM, Scolari S, Pesapane F et al. A Pictorial Exploration of Mammary Paget Disease: Insights and Perspectives. Cancers (Basel). 2023;15(21). doi:10.3390/cancers15215276.
137 .Martella S, Aiello MM, Bertaglia V, Cau R, Denaro N, Cadoni A et al. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors. Target Oncol. 2023. doi:10.1007/s11523-023-01017-w.
138 .McHugh K, Pai RK. Deep Learning and Colon Cancer Interpretation: Rise of the Machine. Surg Pathol Clin. 2023;16(4):651-8. doi:10.1016/j.path.2023.05.003.
139 .Meng Y, Yang Y, Hu M, Zhang Z, Zhou X. Artificial intelligence-based radiomics in bone tumors: Technical advances and clinical application. Semin Cancer Biol. 2023;95:75-87. doi:10.1016/j.semcancer.2023.07.003.
140 .Merchán Gómez B, Milla Collado L, Rodríguez M. Artificial intelligence in esophageal cancer diagnosis and treatment: where are we now?-a narrative review. Ann Transl Med. 2023;11(10):353. doi:10.21037/atm-22-3977.
141 .Miura Y, Osawa H, Sugano K. Recent progress of image-enhanced endoscopy for upper gastrointestinal neoplasia and associated lesions. Dig Dis. 2023. doi:10.1159/000535055.
142 .Mo Y, Adu-Amankwaah J, Qin W, Gao T, Hou X,

Fan M et al. Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis. Ann Med. 2023;55(2):2279748. doi:10.1080/07853890.2023.2279748.
143 .Mohan A, Asghar Z, Abid R, Subedi R, Kumari K, Kumar S et al. Revolutionizing healthcare by use of artificial intelligence in esophageal carcinoma - a narrative review. Ann Med Surg (Lond). 2023;85(10):4920-7. doi:10.1097/ms9.0000000000001175.
144 .Mohseninia N, Zamani-Siahkali N, Harsini S, Divband G, Pirich C, Beheshti M. Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging. Semin Nucl Med. 2024;54(1):97-118. doi:10.1053/j.semnuclmed.2023.07.004.
145 .Muñoz JP, Pérez-Moreno P, Pérez Y, Calaf GM. The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application. Diagnostics (Basel). 2023;13(19). doi:10.3390/diagnostics13193072.
146 .Nagai M, Suzuki S, Minato Y, Ishibashi F, Mochida K, Ohata K et al. Detecting colorectal lesions with image-enhanced endoscopy: an updated review from clinical trials. Clin Endosc. 2023;56(5):553-62. doi:10.5946/ce.2023.055.
147 .Nagi R, Bibra A, Rakesh N, Patil DJ, Vyas T. Artificial intelligence-integrated optical coherence tomography for screening and early detection of oral cancer. Gen Dent. 2024;72(1):46-52.
148 .Nedbal C, Cerrato C, Jahrreiss V, Castellani D,

Pietropaolo A, Galosi AB et al. The role of 'artificial intelligence, machine learning, virtual reality, and radiomics' in PCNL: a review of publication trends over the last 30 years. Ther Adv Urol. 2023;15:17562872231196676. doi:10.1177/17562872231196676.
149 .Nejatie A, Yee SS, Jeter A, Saragovi HU. The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides. Front Oncol. 2023;13:1261090. doi:10.3389/fonc.2023.1261090.
150 .Oh KE, Vasandani N, Anwar A. Radiomics to Differentiate Malignant and Benign Breast Lesions: A Systematic Review and Diagnostic Test Accuracy Meta-Analysis. Cureus. 2023;15(11):e49015. doi:10.7759/cureus.49015.
151 .Orsini A, Diquigiovanni C, Bonora E. Omics Technologies Improving Breast Cancer Research and Diagnostics. Int J Mol Sci. 2023;24(16). doi:10.3390/ijms241612690.
152 .Pai MGJ, Biswas D, Verma A, Srivastava S. A proteome-level view of brain tumors for a better understanding of novel diagnosis, prognosis, and therapy. Expert Rev Proteomics. 2023;20(12):381-95. doi:10.1080/14789450.2023.2283498.
153 .Pan F, Feng L, Liu B, Hu Y, Wang Q. Application of radiomics in diagnosis and treatment of lung cancer. Front Pharmacol. 2023;14:1295511. doi:10.3389/fphar.2023.1295511.
154 .Pan I, Huang RY. Artificial intelligence in

neuroimaging of brain tumors: reality or still promise? Curr Opin Neurol. 2023;36(6):549-56. doi:10.1097/wco.0000000000001213.
155 .Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R et al. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antiviral Res. 2023;220:105740. doi:10.1016/j.antiviral.2023.105740.
156 .Patel K, Huang S, Rashid A, Varghese B, Gholamrezanezhad A. A Narrative Review of the Use of Artificial Intelligence in Breast, Lung, and Prostate Cancer. Life (Basel). 2023;13(10). doi:10.3390/life13102011.
157 .Patel RH, Foltz EA, Witkowski A, Ludzik J. Analysis of Artificial Intelligence-Based Approaches Applied to Non-Invasive Imaging for Early Detection of Melanoma: A Systematic Review. Cancers (Basel). 2023;15(19). doi:10.3390/cancers15194694.
158 .Pesapane F, Battaglia O, Pellegrino G, Mangione E, Petitto S, Fiol Manna ED et al. Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment. Future Oncol. 2023;19(38):2547-64. doi:10.2217/fon-2023-0365.
159 .Pesapane F, Mariano L, Magnoni F, Rotili A, Pupo D, Nicosia L et al. Future Directions in the Assessment of Axillary Lymph Nodes in Patients with Breast Cancer. Medicina (Kaunas). 2023;59(9). doi:10.3390/medicina59091544.
160 .Petrila O, Stefan AE, Gafitanu D, Scripcariu

V, Nistor I. The Applicability of Artificial Intelligence in Predicting the Depth of Myometrial Invasion on MRI Studies-A Systematic Review. Diagnostics (Basel). 2023;13(15). doi:10.3390/diagnostics13152592.
161 .Pierre K, Gupta M, Raviprasad A, Sadat Razavi SM, Patel A, Peters K et al. Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges. Expert Rev Anticancer Ther. 2023;23(12):1265-79. doi:10.1080/14737140.2023.2286001.
162 .Pittara M, Matsangidou M, Pattichis CS. Virtual Reality for Pulmonary Rehabilitation: Comprehensive Review. JMIR Rehabil Assist Technol. 2023;10:e47114. doi:10.2196/47114.
163 .Popovic D, Glisic T, Milosavljevic T, Panic N, Marjanovic-Haljilji M, Mijac D et al. The Importance of Artificial Intelligence in Upper Gastrointestinal Endoscopy. Diagnostics (Basel). 2023;13(18). doi:10.3390/diagnostics13182862.
164 .Prosper AE, Kammer MN, Maldonado F, Aberle DR, Hsu W. Expanding Role of Advanced Image Analysis in CT-detected Indeterminate Pulmonary Nodules and Early Lung Cancer Characterization. Radiology. 2023;309(1):e222904. doi:10.1148/radiol.222904.
165 .Rabilloud N, Allaume P, Acosta O, De Crevoisier R, Bourgade R, Loussouarn D et al. Deep Learning Methodologies Applied to Digital Pathology in Prostate Cancer: A Systematic Review.

Diagnostics (Basel). 2023;13(16). doi:10.3390/diagnostics13162676.
166 .Rahaman A, Anantharaju A, Jeyachandran K, Manideep R, Pal UM. Optical imaging for early detection of cervical cancer: state of the art and perspectives. J Biomed Opt. 2023;28(8):080902. doi:10.1117/1.Jbo.28.8.080902.
167 .Rahimi M, Asadi F. Oncological Applications of Quantum Machine Learning. Technol Cancer Res Treat. 2023;22:15330338231215214. doi:10.1177/15330338231215214.
168 .Ramacciotti LS, Hershenhouse JS, Mokhtar D, Paralkar D, Kaneko M, Eppler M et al. Comprehensive Assessment of MRI-based Artificial Intelligence Frameworks Performance in the Detection, Segmentation, and Classification of Prostate Lesions Using Open-Source Databases. Urol Clin North Am. 2024;51(1):131-61. doi:10.1016/j.ucl.2023.08.003.
169 .Raman AG, Fisher D, Yap F, Oberai A, Duddalwar VA. Radiomics and Artificial Intelligence: Renal Cell Carcinoma. Urol Clin North Am. 2024;51(1):35-45. doi:10.1016/j.ucl.2023.06.007.
170 .Rehman K, Iqbal Z, Zhiqin D, Ayub H, Saba N, Khan MA et al. Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer. Cancer Cell Int. 2023;23(1):247. doi:10.1186/s12935-023-03084-5.
171 .Reinders P, Augustin M, Kirsten N, Fleyder A, Otten M. Digital health interventions in dermatology-Mapping technology

and study parameters of systematically identified publications. J Eur Acad Dermatol Venereol. 2023;37(12):2440-9. doi:10.1111/jdv.19392.
172 .Ren S, Li J, Dorado J, Sierra A, González-Díaz H, Duardo A et al. From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine. Health Inf Sci Syst. 2024;12(1):6. doi:10.1007/s13755-023-00264-5.
173 .Rey JF. Artificial intelligence in digestive endoscopy: recent advances. Curr Opin Gastroenterol. 2023;39(5):397-402. doi:10.1097/mog.0000000000000957.
174 .Riaz S, Naeem A, Malik H, Naqvi RA, Loh WK. Federated and Transfer Learning Methods for the Classification of Melanoma and Nonmelanoma Skin Cancers: A Prospective Study. Sensors (Basel). 2023;23(20). doi:10.3390/s23208457.
175 .Rokhshad R, Salehi SN, Yavari A, Shobeiri P, Esmaeili M, Manila N et al. Deep learning for diagnosis of head and neck cancers through radiographic data: a systematic review and meta-analysis. Oral Radiol. 2023. doi:10.1007/s11282-023-00715-5.
176 .Ronot M, Dioguardi Burgio M, Gregory J, Hentic O, Vullierme MP, Ruszniewski P et al. Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2023;37(5):101827. doi:10.1016/j.beem.2023.101827.

177 .Ryou H, Lomas O, Theissen H, Thomas E, Rittscher J, Royston D. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age? Br J Haematol. 2023;203(4):523-35. doi:10.1111/bjh.19154.
178 .Saft L. The role of flow cytometry in the classification of myeloid disorders. Pathologie (Heidelb). 2023;44(Suppl 3):164-75. doi:10.1007/s00292-023-01272-8.
179 .Sahoo DK, Mishra S, Mohanty MN, Behera RK, Dhar SK. Brain Tumor Detection using Deep Learning Approach. Neurol India. 2023;71(4):647-54. doi:10.4103/0028-3886.383858.
180 .Sahu A, Das PK, Meher S. Recent advancements in machine learning and deep learning-based breast cancer detection using mammograms. Phys Med. 2023;114:103138. doi:10.1016/j.ejmp.2023.103138.
181 .Sala A, Cameron JM, Brennan PM, Crosbie EJ, Curran T, Gray E et al. Global serum profiling: an opportunity for earlier cancer detection. J Exp Clin Cancer Res. 2023;42(1):207. doi:10.1186/s13046-023-02786-y.
182 .Salvioli S, Basile MS, Bencivenga L, Carrino S, Conte M, Damanti S et al. Biomarkers of aging in frailty and age-associated disorders: State of the art and future perspective. Ageing Res Rev. 2023;91:102044. doi:10.1016/j.arr.2023.102044.
183 .Sambyal D, Sarwar A. Recent developments in cervical cancer diagnosis using deep

learning on whole slide images: An Overview of models, techniques, challenges and future directions. Micron. 2023;173:103520. doi:10.1016/j.micron.2023.103520.
184 .Sangers TE, Kittler H, Blum A, Braun RP, Barata C, Cartocci A et al. Position statement of the EADV Artificial Intelligence (AI) Task Force on AI-assisted smartphone apps and web-based services for skin disease. J Eur Acad Dermatol Venereol. 2024;38(1):22-30. doi:10.1111/jdv.19521.
185 .Scarcia M, Moretto S, Zazzara M, Alba S, Fiorentino A, Ciampi L et al. Robot-Assisted Extraperitoneal Radical Prostatectomy for Giant Multilocular Prostatic Cystadenoma: A Case Report and Literature Review. Urol Int. 2023;107(10-12):983-7. doi:10.1159/000534176.
186 .Senevirathna P, Pires DEV, Capurro D. Data-driven overdiagnosis definitions: A scoping review. J Biomed Inform. 2023;147:104506. doi:10.1016/j.jbi.2023.104506.
187 .Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. Diagn Pathol. 2023;18(1):109. doi:10.1186/s13000-023-01375-z.
188 .Shahidi R, Baradaran M, Asgarzadeh A, Bagherieh S, Tajabadi Z, Farhadi A et al. Diagnostic performance of MRI radiomics for classification of Alzheimer's disease, mild cognitive impairment, and normal subjects: a systematic review and meta-analysis. Aging Clin Exp Res. 2023;35(11):2333-48. doi:10.1007/s40520-023-02565-x.
189 .Shahsavari D, Waqar M, Thoguluva

Chandrasekar V. Image enhanced colonoscopy: updates and prospects-a review. Transl Gastroenterol Hepatol. 2023;8:26. doi:10.21037/tgh-23-17.
190 .Sharma P, Nayak DR, Balabantaray BK, Tanveer M, Nayak R. A survey on cancer detection via convolutional neural networks: Current challenges and future directions. Neural Netw. 2024;169:637-59. doi:10.1016/j.neunet.2023.11.006.
191 .Shiraishi K. Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire. Int J Urol. 2023;30(11):959-67. doi:10.1111/iju.15264.
192 .Shu Y, Xu W, Su R, Ran P, Liu L, Zhang Z et al. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis. Front Immunol. 2023;14:1251645. doi:10.3389/fimmu.2023.1251645.
193 .Singh M, Anvekar P, Baraskar B, Pallipamu N, Gadam S, Cherukuri ASS et al. Prospective of Pancreatic Cancer Diagnosis Using Cardiac Sensing. J Imaging. 2023;9(8). doi:10.3390/jimaging9080149.
194 .Slabaugh G, Beltran L, Rizvi H, Deloukas P, Marouli E. Applications of machine and deep learning to thyroid cytology and histopathology: a review. Front Oncol. 2023;13:958310. doi:10.3389/fonc.2023.958310.
195 .Smit JM, Krijthe JH, Kant WMR, Labrecque JA,

Komorowski M, Gommers D et al. Causal inference using observational intensive care unit data: a scoping review and recommendations for future practice. NPJ Digit Med. 2023;6(1):221. doi:10.1038/s41746-023-00961-1.
196 .Srivastava S, Jayaswal N, Kumar S, Sharma PK, Behl T, Khalid A et al. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management. Cell Signal. 2024;113:110932. doi:10.1016/j.cellsig.2023.110932.
197 .Stolzenbach LF, Fankhauser CD, Mattei A, Würnschimmel C. Solitary Fibrous Tumor of the Prostate Treated with Frozen-Section Supported Robot-Assisted Nerve-Sparing Radical Prostatectomy. Urol Int. 2023;107(10-12):977-82. doi:10.1159/000534088.
198 .Stossi F, Singh PK, Safari K, Marini M, Labate D, Mancini MA. High throughput microscopy and single cell phenotypic image-based analysis in toxicology and drug discovery. Biochem Pharmacol. 2023;216:115770. doi:10.1016/j.bcp.2023.115770.
199 .Sufyan M, Shokat Z, Ashfaq UA. Artificial intelligence in cancer diagnosis and therapy: Current status and future perspective. Comput Biol Med. 2023;165:107356. doi:10.1016/j.compbiomed.2023.107356.
200 .Sugano K, Moss SF, Kuipers EJ. Gastric Intestinal Metaplasia: Real Culprit or Innocent Bystander as a Precancerous Condition for Gastric Cancer? Gastroenterology. 2023;165(6):1352-66.e1.

doi:10.1053/j.gastro.2023.08.028.
201 .Suh A, Ong J, Kamran SA, Waisberg E, Paladugu P, Zaman N et al. Retina Oculomics in Neurodegenerative Disease. Ann Biomed Eng. 2023;51(12):2708-21. doi:10.1007/s10439-023-03365-0.
202 .Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8(1):418. doi:10.1038/s41392-023-01642-x.
203 .Swanson AA, Pantanowitz L. The evolution of cervical cancer screening. J Am Soc Cytopathol. 2023. doi:10.1016/j.jasc.2023.09.007.
204 .Szalai C. Arguments for and against the whole-genome sequencing of newborns. Am J Transl Res. 2023;15(10):6255-63.
205 .Tan N, Pollock JR, Margolis DJA, Padhani AR, Tempany C, Woo S et al. Management of Patients With a Negative Multiparametric Prostate MRI Examination: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2023. doi:10.2214/ajr.23.29969.
206 .Tangsrivimol JA, Schonfeld E, Zhang M, Veeravagu A, Smith TR, Härtl R et al. Artificial Intelligence in Neurosurgery: A State-of-the-Art Review from Past to Future. Diagnostics (Basel). 2023;13(14). doi:10.3390/diagnostics13142429.
207 .Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang TW et al. Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management.

Eur Radiol. 2023;33(12):9152-66. doi:10.1007/s00330-023-09928-y.
208 .Thalakottor LA, Shirwaikar RD, Pothamsetti PT, Mathews LM. Classification of Histopathological Images from Breast Cancer Patients Using Deep Learning: A Comparative Analysis. Crit Rev Biomed Eng. 2023;51(4):41-62. doi:10.1615/CritRevBiomedEng.2023047793.
209 .Thomas J, Ravichandran R, Nag A, Gupta L, Singh M, Panjiyar BK. Advancing Colorectal Cancer Screening: A Comprehensive Systematic Review of Artificial Intelligence (AI)-Assisted Versus Routine Colonoscopy. Cureus. 2023;15(9):e45278. doi:10.7759/cureus.45278.
210 .Timakova A, Ananev V, Fayzullin A, Makarov V, Ivanova E, Shekhter A et al. Artificial Intelligence Assists in the Detection of Blood Vessels in Whole Slide Images: Practical Benefits for Oncological Pathology. Biomolecules. 2023;13(9). doi:10.3390/biom13091327.
211 .Tiwari A, Gupta N, Singla D, Ranjan Swain J, Gupta R, Mehta D et al. Artificial Intelligence's Use in the Diagnosis of Mouth Ulcers: A Systematic Review. Cureus. 2023;15(9):e45187. doi:10.7759/cureus.45187.
212 .Tjandra D, Busuttil RA, Boussioutas A. Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention. Cancers (Basel). 2023;15(15). doi:10.3390/cancers15153913.
213 .To KKW, Cho WC. Drug

Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy. Pharmaceutics. 2023;15(8). doi:10.3390/pharmaceutics15082166.
214 .Tsunedomi R, Shindo Y, Nakajima M, Yoshimura K, Nagano H. The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers. Expert Rev Mol Diagn. 2023;23(12):1121-34.
doi:10.1080/14737159.2023.2281482.
215 .Ueda T, Li JW, Ho SH, Singh R, Uedo N. Precision endoscopy in the era of climate change and sustainability. J Gastroenterol Hepatol. 2023. doi:10.1111/jgh.16383.
216 .Vadhwana B, Tarazi M, Patel V. The Role of Artificial Intelligence in Prospective Real-Time Histological Prediction of Colorectal Lesions during Colonoscopy: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2023;13(20). doi:10.3390/diagnostics13203267.
217 .Valeri A, Nguyen TA. Research on texture images and radiomics in urology: a review of urological MR imaging applications. Curr Opin Urol. 2023;33(6):428-36. doi:10.1097/mou.0000000000001131.
218 .van Nijnatten TJA, Payne NR, Hickman SE, Ashrafian H, Gilbert FJ. Overview of trials on artificial intelligence algorithms in breast cancer screening - A roadmap for international evaluation and implementation.

Eur J Radiol. 2023;167:111087. doi:10.1016/j.ejrad.2023.111087.
219 .Vargas-Cardona HD, Rodriguez-Lopez M, Arrivillaga M, Vergara-Sanchez C, García-Cifuentes JP, Bermúdez PC et al. Artificial intelligence for cervical cancer screening: Scoping review, 2009-2022. Int J Gynaecol Obstet. 2023. doi:10.1002/ijgo.15179.
220 .Verghese G, Lennerz JK, Ruta D, Ng W, Thavaraj S, Siziopikou KP et al. Computational pathology in cancer diagnosis, prognosis, and prediction - present day and prospects. J Pathol. 2023;260(5):551-63. doi:10.1002/path.6163.
221 .Vigdorovits A, Köteles MM, Olteanu GE, Pop O. Breaking Barriers: AI's Influence on Pathology and Oncology in Resource-Scarce Medical Systems. Cancers (Basel). 2023;15(23). doi:10.3390/cancers15235692.
222 .Vitali F, Zundler S, Jesper D, Wildner D, Strobel D, Frulloni L et al. Diagnostic Endoscopic Ultrasound in Pancreatology: Focus on Normal Variants and Pancreatic Masses. Visc Med. 2023;39(5):121-30. doi:10.1159/000533432.
223 .Vocino Trucco G, Righi L, Volante M, Papotti M. Updates on lung neuroendocrine neoplasm classification. Histopathology. 2024;84(1):67-85. doi:10.1111/his.15058.
224 .Wang H, Chen X, He L. A narrative review of radiomics and deep learning advances in neuroblastoma: updates and challenges. Pediatr Radiol. 2023;53(13):2742-55. doi:10.1007/

s00247-023-05792-6.
225 .Wang R, Xiong K, Wang Z, Wu D, Hu B, Ruan J et al. Immunodiagnosis - the promise of personalized immunotherapy. Front Immunol. 2023;14:1216901. doi:10.3389/fimmu.2023.1216901.
226 .Wang X, Hu X, Xu Y, Yong J, Li X, Zhang K et al. A systematic review on diagnosis and treatment of gastrointestinal diseases by magnetically controlled capsule endoscopy and artificial intelligence. Therap Adv Gastroenterol. 2023;16:17562848231206991. doi:10.1177/17562848231206991.
227 .Wang Y, Li N, Chen L, Wu M, Meng S, Dai Z et al. Guidelines, Consensus Statements, and Standards for the Use of Artificial Intelligence in Medicine: Systematic Review. J Med Internet Res. 2023;25:e46089. doi:10.2196/46089.
228 .Wang Z, Liang X, Wang G, Wang X, Chen Y. Emerging Bioprinting for Wound Healing. Adv Mater. 2023:e2304738. doi:10.1002/adma.202304738.
229 .Waqas A, Bui MM, Glassy EF, El Naqa I, Borkowski P, Borkowski AA et al. Revolutionizing Digital Pathology With the Power of Generative Artificial Intelligence and Foundation Models. Lab Invest. 2023;103(11):100255. doi:10.1016/j.labinv.2023.100255.
230 .Waseh S, Lee JB. Advances in melanoma: epidemiology, diagnosis, and prognosis. Front Med (Lausanne). 2023;10:1268479. doi:10.3389/

fmed.2023.1268479.
231 .Weerarathna IN, Kamble AR, Luharia A. Artificial Intelligence Applications for Biomedical Cancer Research: A Review. Cureus. 2023;15(11):e48307. doi:10.7759/cureus.48307.
232 .Wei L, Niraula D, Gates EDH, Fu J, Luo Y, Nyflot MJ et al. Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. Br J Radiol. 2023;96(1150):20230211. doi:10.1259/bjr.20230211.
233 .Westendorp J, Geerse OP, van der Lee ML, Schoones JW, van Vliet MHM, Wit T et al. Harmful communication behaviors in cancer care: A systematic review of patients and family caregivers perspectives. Psychooncology. 2023;32(12):1827-38. doi:10.1002/pon.6247.
234 .Windsor GO, Bai H, Lourenco AP, Jiao Z. Application of artificial intelligence in predicting lymph node metastasis in breast cancer. Front Radiol. 2023;3:928639. doi:10.3389/fradi.2023.928639.
235 .Woernle A, Englman C, Dickinson L, Kirkham A, Punwani S, Haider A et al. Picture Perfect: The Status of Image Quality in Prostate MRI. J Magn Reson Imaging. 2023. doi:10.1002/jmri.29025.
236 .Wojtara MS, Kang J, Zaman M. Congenital Telangiectatic Erythema: Scoping Review. JMIR Dermatol. 2023;6:e48413. doi:10.2196/48413.
237 .Wong EY, Chu TN, Ladi-Seyedian SS. Genomics and Artificial Intelligence: Prostate Cancer. Urol

Clin North Am. 2024;51(1):27-33. doi:10.1016/j.ucl.2023.06.006.
238 .Wu J, Liang B, Lu S, Xie J, Song Y, Wang L et al. Application of 3D printing technology in tumor diagnosis and treatment. Biomed Mater. 2023;19(1). doi:10.1088/1748-605X/ad08e1.
239 .Wu Y, Li Y, Xiong X, Liu X, Lin B, Xu B. Recent advances of pathomics in colorectal cancer diagnosis and prognosis. Front Oncol. 2023;13:1094869. doi:10.3389/fonc.2023.1094869.
240 .Xin Y, Zhang Q, Liu X, Li B, Mao T, Li X. Application of artificial intelligence in endoscopic gastrointestinal tumors. Front Oncol. 2023;13:1239788. doi:10.3389/fonc.2023.1239788.
241 .Yaghoubi Naei V, Bordhan P, Mirakhorli F, Khorrami M, Shrestha J, Nazari H et al. Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA. Ther Adv Med Oncol. 2023;15:17588359231192401. doi:10.1177/17588359231192401.
242 .Yan S, Li J, Wu W. Artificial intelligence in breast cancer: application and future perspectives. J Cancer Res Clin Oncol. 2023;149(17):16179-90. doi:10.1007/s00432-023-05337-2.
243 .Yao L, Zhang Z, Keles E, Yazici C, Tirkes T, Bagci U. A review of deep learning and radiomics approaches for pancreatic cancer diagnosis from medical imaging. Curr Opin Gastroenterol. 2023;39(5):436-47. doi:10.1097/

mog.0000000000000966.
244 .Yao X, Kumar MV, Su E, Flores Miranda A, Saha A, Sussman J. Evaluating the efficacy of artificial intelligence tools for the automation of systematic reviews in cancer research: A systematic review. Cancer Epidemiol. 2023;88:102511. doi:10.1016/j.canep.2023.102511.
245 .You C, Shen Y, Sun S, Zhou J, Li J, Su G et al. Artificial intelligence in breast imaging: Current situation and clinical challenges. Exploration (Beijing). 2023;3(5):20230007. doi:10.1002/exp.20230007.
246 .Young E, Edwards L, Singh R. The Role of Artificial Intelligence in Colorectal Cancer Screening: Lesion Detection and Lesion Characterization. Cancers (Basel). 2023;15(21). doi:10.3390/cancers15215126.
247 .Yousif M, Pantanowitz L. Artificial Intelligence-Enabled Gastric Cancer Interpretations: Are We There yet? Surg Pathol Clin. 2023;16(4):673-86. doi:10.1016/j.path.2023.05.005.
248 .Zarella MD, McClintock DS, Batra H, Gullapalli RR, Valante M, Tan VO et al. Artificial intelligence and digital pathology: clinical promise and deployment considerations. J Med Imaging (Bellingham). 2023;10(5):051802. doi:10.1117/1.Jmi.10.5.051802.
249 .Zha Y, Xue C, Liu Y, Ni J, De La Fuente JM, Cui D. Artificial intelligence in theranostics of gastric cancer, a review. Med Rev (2021). 2023;3(3):214-29. doi:10.1515/mr-2022-0042.

250 .Zhang C, Xu J, Tang R, Yang J, Wang W, Yu X et al. Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment. J Hematol Oncol. 2023;16(1):114. doi:10.1186/s13045-023-01514-5.
251 .Zhang H, Xi Q, Zhang F, Li Q, Jiao Z, Ni X. Application of Deep Learning in Cancer Prognosis Prediction Model. Technol Cancer Res Treat. 2023;22:15330338231199287. doi:10.1177/15330338231199287.
252 .Zhang J, Wu J, Zhou XS, Shi F, Shen D. Recent advancements in artificial intelligence for breast cancer: Image augmentation, segmentation, diagnosis, and prognosis approaches. Semin Cancer Biol. 2023;96:11-25. doi:10.1016/j.semcancer.2023.09.001.
253 .Zhang L, Yao L, Lu Z, Yu H. Current status of quality control in screening esophagogastroduodenoscopy and the emerging role of artificial intelligence. Dig Endosc. 2023. doi:10.1111/den.14649.
254 .Zhang X, Liu B, Liu K, Wang L. The diagnosis performance of convolutional neural network in the detection of pulmonary nodules: a systematic review and meta-analysis. Acta Radiol. 2023;64(12):2987-98. doi:10.1177/02841851231201514.
255 .Zhang X, Peng J, Ji G, Li T, Li B, Xiong H. Research status and progress of radiomics in bone and soft tissue tumors: A review. Medicine (Baltimore). 2023;102(47):e36196. doi:10.1097/

md.0000000000036198.
256 .Zhang Y, Yuan Q, Muzzammil HM, Gao G, Xu Y. Image-guided prostate biopsy robots: A review. Math Biosci Eng. 2023;20(8):15135-66. doi:10.3934/mbe.2023678.
257 .Zhao Y, Guo Q, Zhang Y, Zheng J, Yang Y, Du X et al. Application of Deep Learning for Prediction of Alzheimer's Disease in PET/MR Imaging. Bioengineering (Basel). 2023;10(10). doi:10.3390/bioengineering10101120.
258 .Zhu J, Yang Y, Wong HM. Development and accuracy of artificial intelligence-generated prediction of facial changes in orthodontic treatment: a scoping review. J Zhejiang Univ Sci B. 2023;24(11):974-84. doi:10.1631/jzus.B2300244.
259 .Zhu X, Shao L, Liu Z, Liu Z, He J, Liu J et al. MRI-derived radiomics models for diagnosis, aggressiveness, and prognosis evaluation in prostate cancer. J Zhejiang Univ Sci B. 2023;24(8):663-81. doi:10.1631/jzus.B2200619.
260 .Zidane M, Makky A, Bruhns M, Rochwarger A, Babaei S, Claassen M et al. A review on deep learning applications in highly multiplexed tissue imaging data analysis. Front Bioinform. 2023;3:1159381. doi:10.3389/fbinf.2023.1159381.
261 .Farrokhi M, Rigi A, Mangouri A, Fadaei M, Shabani E, Mashouf P et al. Role of Antioxidants in Autoimmune Diseases. Kindle. 2021;1(1):1-107.
262 .Farrokhi M, Shabani S, Rigi A, Seighalani HH, Pazhooha M, Bagheri S et al. Academic Textbook: Anatomy, Pathophysiology, and Treatment of Pain.

Kindle. 2023;3(1):1-123.
263 .Farrokhi M, Vafaei S, Bidares M, Siami H, Rigi A, Hannaniyan M et al. Diagnosis and Treatment of Manifestations of COVID-19. Kindle. 2021;1(1):1-170.
264 .Yarmohammadi B, Rigi A, Sahebkar F, Ahadiat S-A, Gharei F, Heydarian P et al. Guidelines for Providing Services in Medical Departments During the COVID-19 Pandemic. Kindle. 2022;2(1):1-193.
265 .Ahadiat S-A, Shirazinia M, Shirazinia S, Garousi S, Mottahedi M, Jalali AB et al. Role of Telemedicine in Management of Patients During the COVID-19 Pandemic. Kindle. 2022;2(1):1-191.
266 .Abadi SAH, Atbaei R, Forouhi M, Falaverjani HG, Moazamiyanfar R, Rezaei M et al. Preventive and Therapeutic Approaches in Medical Departments During the COVID-19 Pandemic. Kindle. 2022;2(1):1-216.
267 .Ahadiat S-A, Ghazalgoo A, Abadi SAH, Falaverjani HG, Bagherianlemraski M, Namazifar F et al. Role of Vitamin D in Pathogenesis, Diagnosis, and Treatment of Inflammatory Diseases. Kindle. 2022;2(1):1-119.
268 .Ahadiat S-A, Atighi J, Forouhi M, Mashatan N, Ghahremaniyeh Z, Radmanesh M et al. Diagnosis and Management of Complications of COVID-19. Kindle. 2022;2(1):1-113.
269 .Tabatabaei SOH, Moazamiyanfar R, Fard AM, Salemi MH, Masjedi MNK, Yazdani Y et al. Academic Textbook: The Role of Melatonin in Pathogenesis and Treatment of Autoimmune Diseases. Kindle.

2023;3(1):1-126.
270 .Ahadiat S-A, Falaverjani HG, Shabani M, Abadi SAH, Moazamiyanfar R, Rajabi SK et al. The Role of Stem Cells in Treatment of Autoimmune Diseases. Kindle. 2022;2(1):1-136.
271 .Fard AM, Nikbakht T, Babaei N, Pouyamanesh M, Afzalian A, Kharazmkia A et al. Role of Medicinal Plants in Treatment of Inflammatory Diseases. Kindle. 2022;2(1):1-139.
272 .Ahadiat S-A, Barati R, Moghadam NS, Samami E, Ghiabi S, Alyari M et al. Role of Oxidative Stress and Antioxidants in Malignancies. Kindle. 2022;2(1):1-122.
273 .Ahadiat S-A, Kamrani K, Fard AM, Bagherianlemraski M, Rahimpour E, Jamali M et al. Role of Blood Groups in Risk, Severity, Prognosis, and Response to Treatment of the Diseases. Kindle. 2022;2(1):1-130.
274 .Ghalamkarpour N, Fard AM, Babazadeh A, Nikseresht H, Feyzmanesh A, Soltani R et al. Role of Biomarkers in Risk, Diagnosis, Response to Treatment, and Prognosis of the Autoimmune Diseases. Kindle. 2022;2(1):1-124.
275 .Talaie R, Fard SS, Forouhi M, Fard AM, Fard TM, Dadashzadehasl N et al. Applications, Limitations, and Guidelines for the Use of Telemedicine in Medical Departments. Kindle. 2022;2(1):1-118.
276 .Rahmani E, Fard AM, Baghsheikhi H, Hosseini Z, Mashaollahi A, Atighi J et al. Role of Selenium in Pathogenesis and Treatment of the Autoimmune Diseases. Kindle. 2022;2(1):1-131.

277 .Poudineh S, Poudineh M, Roohinezhad R, Khorram R, Fard AM, Barzegar F et al. Role of Vitamins in Pathogenesis and Treatment of Cancers. Kindle. 2023;3(1):1-110.
278 .Poudineh M, Poudineh S, Hosseini Z, Pouramini S, Fard SS, Fadavian H et al. Risk Factors for the Development of Cancers. Kindle. 2023;3(1):1-118.
279 .Amini N, Azimzadeh M, Dosar MD, Fard AM, Habibzadeh N, Yahyazadehjasour S et al. Role of Microbiome, Infection, and Inflammation in Autoimmune Diseases. Kindle. 2023;3(1):1-102.
280 .Taheri F, Farrokhi M, Fard AM, Rahmani E, Soltani R, Shamsedanesh S et al. Role of Micronutrients and Nutrition in Prevention and Treatment of Cancers. Kindle. 2023;3(1):1-102.
281 .Taheri F, Rahmani E, Fard SS, Rezaei M, Ayati A, Farhoudian A et al. Aging Process and Related Diseases. Kindle. 2023;3(1):1-117.
282 .Rahmani E, Rezaei M, Tavakoli R, Ghadirzadeh E, Sarnaghy FJ, Khorram R et al. Role of Regenerative Medicine in the Treatment of Diseases. Kindle. 2023;3(1):1-184.
283 .Rezaei M, Rahmani E, Khouzani SJ, Rahmannia M, Ghadirzadeh E, Bashghareh P et al. Role of Artificial Intelligence in the Diagnosis and Treatment of Diseases. Kindle. 2023;3(1):1-160.
284 .Farrokhi M, Taheri F, Khouzani PJ, Rahmani E, Tavakoli R, Fard AM et al. Role of Precision Medicine and Personalized Medicine in the Treatment of Diseases. Kindle. 2023;3(1):1-164.
285 .Farrokhi M, Taheri F, Karami E, Khorram

R, Sarnaghy FJ, Mirbolook A et al. Effects of Environmental Factors and Epigenetic on Health and the Development of Diseases. Kindle. 2023;3(1):1-186.
286 .Farrokhi M, Taheri F, Moeini A, Farrokhi M, Rabiei S, Farahmandsadr M et al. Sex and Gender Differences in the Pathogenesis and Treatment of Diseases. Kindle. 2023;3(1):1-168.
287 .Rezaei T, Khouzani PJ, Khouzani SJ, Fard AM, Rashidi S, Ghazalgoo A et al. Integrating Artificial Intelligence into Telemedicine: Revolutionizing Healthcare Delivery. Kindle. 2023;3(1):1-161.
288 .Farrokhi M, Moeini A, Taheri F, Farrokhi M, Mostafavi M, Ardakan AK et al. Artificial Intelligence in Cancer Care: From Diagnosis to Prevention and Beyond. Kindle. 2023;3(1):1-149.
289 .Rezaei M, Saei S, Khouzani SJ, Rostami ME, Rahmannia M, Manzelat AMR, et al. Emerging Technologies in Medicine: Artificial Intelligence, Robotics, and Medical Automation. Kindle. 2023;3(1):1-184.
290 .Farrokhi M, Moeini A, Taheri F, Farrokhi M, Khodashenas M, Babaei M, Khouzani PJ, Nikseresht H, Shafiei D, Shayankia G, Shayankia A. AI-assisted Screening and Prevention Programs for Diseases. Kindle. 2023 Dec 12;3(1):1-209.

Proof